{"parentUuid":null,"isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":"You are doing R2 creative brainstorming for Phase 6 of a ME/CFS documentation project. The goal is to discover biological phenomena, treatment ideas, hypotheses, and research questions BEFORE any drafting begins.\n\n## Topic: Phase 6 ‚Äî Medication Effect Patterns in ME/CFS\n\nPhase 6 documents 6 types of medication effect patterns that are poorly understood and often cause harm when not anticipated:\n\n1. **Transient adverse effects** ‚Äî Side effects that appear early and resolve with continued treatment (e.g., LDN initial insomnia, SSRIs initial anxiety)\n2. **Therapeutic lag** ‚Äî Delay between starting medication and clinical benefit (e.g., amitriptyline weeks to months for pain, B12 months for neurological recovery)\n3. **Herxheimer reactions** ‚Äî Worsening symptoms upon starting antimicrobials (suggested in ME/CFS treatment)\n4. **Energy-before-mood paradox** ‚Äî Critical safety issue: stimulating treatments may restore physical energy before emotional/cognitive stability returns, creating risk period\n5. **Dose-dependent benefit curves** ‚Äî Non-linear dose responses (e.g., LDN: too low = no effect, too high = worse, optimal window; melatonin: 0.5mg may be better than 5mg for circadian)\n6. **Withdrawal effects** ‚Äî Symptoms upon discontinuation (e.g., corticosteroid discontinuation, SSRIs, opioids, antihistamines)\n\n## Your Task\n\n### A. Additional Effect Patterns (beyond the 6 planned)\nWhat other poorly-understood medication effect patterns occur in ME/CFS? Consider:\n- Paradoxical responses (e.g., stimulants causing sedation in some patients)\n- Accumulation effects (drugs that build up over weeks)\n- Drug-trigger interactions (medications that can trigger PEM)\n- Nocebo effects specific to ME/CFS patient population\n- Individual metabolizer variation (CYP450 polymorphisms)\n- Drug-nutrient interactions\n- Chronopharmacology (time-of-day effects)\n- First-dose phenomena\n- Rebound effects vs. withdrawal effects distinction\n\n### B. For Each of the 6 Planned Effect Types (‚â•3 per type):\n- **Additional sub-patterns** within this effect type\n- **Treatment implications** (what should clinicians/patients do?)\n- **Research questions** specific to this pattern\n\n### C. Patient Case Cross-Reference\nWhat medication response patterns would be especially important to document for:\n- A patient with: moderate-severe ME/CFS, dysautonomia, MCAS, tinnitus, cognitive impairment\n- Key medications this patient might be taking: LDN, antihistamines, beta-blockers, melatonin, supplements (CoQ10, B12, magnesium, lipoic acid)\n\n### D. Pediatric Adaptations\n- Which of the 6 effect types are especially important for pediatric patients?\n- What pediatric-specific variations exist?\n- Are there developmental considerations?\n\n### E. Safety Considerations\n- Which patterns are most dangerous if unrecognized?\n- What monitoring is needed?\n- Patient education priorities\n\n## Minimum Deliverables\n- ‚â•3 additional effect patterns beyond the 6 planned\n- ‚â•18 sub-patterns total (‚â•3 per planned type)\n- ‚â•18 treatment implications total\n- ‚â•18 research questions total\n\n## Output Format\n\n### A. Additional Effect Patterns\n[numbered list with description and rationale for inclusion]\n\n### B. Per-Type Analysis\n#### Type 1: Transient Adverse Effects\n#### Type 2: Therapeutic Lag\n#### Type 3: Herxheimer Reactions\n#### Type 4: Energy-Before-Mood Paradox\n#### Type 5: Dose-Dependent Benefit Curves\n#### Type 6: Withdrawal Effects\n\n### C. Patient Case Application\n### D. Pediatric Adaptations\n### E. Safety Priority Ranking"},"uuid":"dcdbc689-fd1d-4c1a-ac18-97988e19c5ae","timestamp":"2026-02-17T19:24:26.879Z"}
{"parentUuid":"dcdbc689-fd1d-4c1a-ac18-97988e19c5ae","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_0135sAtcqU3w9JcLzBKKEg77","type":"message","role":"assistant","content":[{"type":"text","text":"\n\nüìä Context: ~5% (estimated ~10,000 / 200,000 tokens)\n\nLet me first gather relevant context from the project to ground this brainstorming in the existing documentation and patient case data."}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":3,"cache_creation_input_tokens":5366,"cache_read_input_tokens":5277,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":5366},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBsNu4dCfw1uYVCSgHx","type":"assistant","uuid":"cc487dc5-ac91-4fe9-9a22-4b0a922bcaea","timestamp":"2026-02-17T19:24:31.594Z"}
{"parentUuid":"cc487dc5-ac91-4fe9-9a22-4b0a922bcaea","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_0135sAtcqU3w9JcLzBKKEg77","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","name":"Grep","input":{"pattern":"medication|drug|pharmacol|dose|LDN|naltrexone|antihistamine|melatonin","path":"/home/nicky/code/health-me-cfs/patients/yannick","output_mode":"files_with_matches"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":3,"cache_creation_input_tokens":5366,"cache_read_input_tokens":5277,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":5366},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBsNu4dCfw1uYVCSgHx","type":"assistant","uuid":"3cad55ad-072d-42c4-a8e5-33a965e2c43c","timestamp":"2026-02-17T19:24:33.346Z"}
{"parentUuid":"3cad55ad-072d-42c4-a8e5-33a965e2c43c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","toolUseID":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","timestamp":"2026-02-17T19:24:33.502Z","uuid":"75e422d5-c5c3-430e-b6ad-14fbdd277c81"}
{"parentUuid":"75e422d5-c5c3-430e-b6ad-14fbdd277c81","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","toolUseID":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","timestamp":"2026-02-17T19:24:33.502Z","uuid":"bb4a9495-5664-4ddb-b94c-34ce1076ee99"}
{"parentUuid":"3cad55ad-072d-42c4-a8e5-33a965e2c43c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01VZ8VWFavD3QMYXWYs9nEpZ","type":"tool_result","content":"Found 41 files\npatients/yannick/medical report/contents/12-analyse-cas.tex\npatients/yannick/medical report/contents/15-recommandations.tex\npatients/yannick/medical report/contents/02-historique-patient.tex\npatients/yannick/medical report/contents/06-gestion-medicale.tex\npatients/yannick/medical report/contents/04-profil-symptomatique.tex\npatients/yannick/medical report/contents/07-recommandations-traitement.tex\npatients/yannick/medical report/contents/10-surveillance-interactions.tex\npatients/yannick/medical report/contents/14-references.tex\npatients/yannick/medical report/contents/13-hypotheses-cliniques.tex\npatients/yannick/medical report/contents/11-interventions-quotidiennes.tex\npatients/yannick/medical report/contents/05-evenements-recents.tex\npatients/yannick/medical report/contents/01-resume-executif.tex\npatients/yannick/case-data/symptoms/202602/2026-02-16.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-15.yaml\npatients/yannick/case-data/recommendations.tex\npatients/yannick/case-data/symptoms/202602/2026-02-13.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-14.yaml\npatients/yannick/protocols/20260122/medication-protocol-quick-reference.tex\npatients/yannick/case-data/symptoms/202602/2026-02-12.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-11.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-10.yaml\npatients/yannick/README.md\npatients/yannick/protocols/sleep-tracking-protocol.tex\npatients/yannick/protocols/sleep-specialist-referral.tex\npatients/yannick/protocols/diagnostic-test-protocol.tex\npatients/yannick/00-index.tex\npatients/yannick/case-data/events/2026-02-10_autonomic-dysregulation-critical.md\npatients/yannick/case-data/symptoms/202602/2026-02-09.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-08.yaml\npatients/yannick/case-data/symptoms/202602/2026-02-02.yaml\npatients/yannick/case-data/CASE_JOURNAL_2026-01-30_31.md\npatients/yannick/case-data/patterns/electrolyte-induced-pain-crash.yaml\npatients/yannick/case-data/symptoms/202601/2026-01-31.yaml\npatients/yannick/case-data/symptoms/202601/2026-01-30.yaml\npatients/yannick/case-data/DOCUMENTATION_UPDATE_2026-01-30.md\npatients/yannick/case-data/causal-models/multi-hit-pathway-to-mecfs.yaml\npatients/yannick/case-data/patterns/vasovagal-hypersensitivity.yaml\npatients/yannick/case-data/historical-exposures/childhood-fluoride-zyma-fluor.yaml\npatients/yannick/case-data/symptoms/202601/2026-01-26.yaml\npatients/yannick/case-data/symptoms/202601/2026-01-25.yaml\npatients/yannick/case-data/README.md"}]},"uuid":"52147d69-cae9-4233-a4c4-1ab57d818860","timestamp":"2026-02-17T19:24:33.502Z","sourceToolAssistantUUID":"3cad55ad-072d-42c4-a8e5-33a965e2c43c"}
{"parentUuid":"52147d69-cae9-4233-a4c4-1ab57d818860","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_0135sAtcqU3w9JcLzBKKEg77","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_014TLmysNBAE5GyKRn1KHcaJ","name":"Grep","input":{"pattern":"paradox|transient|herxheimer|withdrawal|rebound|lag","path":"/home/nicky/code/health-me-cfs/contents","output_mode":"files_with_matches"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":3,"cache_creation_input_tokens":5366,"cache_read_input_tokens":5277,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":5366},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBsNu4dCfw1uYVCSgHx","type":"assistant","uuid":"1d15b7d5-9186-4eb9-a4b1-a65ff70696e2","timestamp":"2026-02-17T19:24:34.353Z"}
{"parentUuid":"1d15b7d5-9186-4eb9-a4b1-a65ff70696e2","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_014TLmysNBAE5GyKRn1KHcaJ","toolUseID":"toolu_014TLmysNBAE5GyKRn1KHcaJ","timestamp":"2026-02-17T19:24:34.478Z","uuid":"cca5368e-234f-4d3d-815c-3ad0df27fb57"}
{"parentUuid":"cca5368e-234f-4d3d-815c-3ad0df27fb57","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_014TLmysNBAE5GyKRn1KHcaJ","toolUseID":"toolu_014TLmysNBAE5GyKRn1KHcaJ","timestamp":"2026-02-17T19:24:34.478Z","uuid":"f1111a2e-35cb-4f01-a568-86cbfdb91514"}
{"parentUuid":"1d15b7d5-9186-4eb9-a4b1-a65ff70696e2","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_014TLmysNBAE5GyKRn1KHcaJ","type":"tool_result","content":"Found 43 files\ncontents/appendices/appendix-h-annotated-bibliography.tex\ncontents/part3-treatment/ch17-lifestyle-interventions.tex\ncontents/part2-pathophysiology/ch10-cardiovascular.tex\ncontents/part3-treatment/ch14a-urgent-action-severe.tex\ncontents/part3-treatment/ch14b-action-mild-moderate.tex\ncontents/part2-pathophysiology/ch14/ch14j-selective-dysfunction.tex\ncontents/part2-pathophysiology/ch08-neurological.tex\ncontents/part2-pathophysiology/ch07-immune-dysfunction.tex\ncontents/part1-clinical/ch03-additional-symptoms.tex\ncontents/part1-clinical/ch02-core-symptoms.tex\ncontents/part2-pathophysiology/ch13-integrative-models.tex\ncontents/part2-pathophysiology/ch11-gut-microbiome.tex\ncontents/part2-pathophysiology/ch09-endocrine.tex\ncontents/part3-treatment/ch18-emerging-therapies.tex\ncontents/part4-research/ch25b-proposed-studies.tex\ncontents/part3-treatment/ch14c-pediatric-severe.tex\ncontents/appendices/appendix-g-research-synthesis.tex\ncontents/part4-research/ch25-translational-findings.tex\ncontents/part3-treatment/ch15-medications-systems.tex\ncontents/part1-clinical/ch05-subgroups.tex\ncontents/part1-clinical/ch04-sections/ch04-08-differential-diagnosis.tex\ncontents/part2-pathophysiology/ch06-energy-metabolism.tex\ncontents/part1-clinical/ch05-prognosis.tex\ncontents/appendices/appendix-d-resources.tex\ncontents/part1-clinical/ch05-progression.tex\ncontents/part2-pathophysiology/ch14/ch14i-clinical-brainstorm.tex\ncontents/part3-treatment/ch16-supplements-nutraceuticals.tex\ncontents/part4-research/ch25a-research-infrastructure.tex\ncontents/part1-clinical/ch04-sections/ch04-07-novel-framework.tex\ncontents/part2-pathophysiology/ch14/ch14f-cpet-derived.tex\ncontents/part1-clinical/ch01-introduction.tex\ncontents/part2-pathophysiology/ch12-genetics-epigenetics.tex\ncontents/appendices/appendix-f-supplement-guide.tex\ncontents/part5-modeling/ch31-temporal-evolution.tex\ncontents/part4-research/ch23-epidemiology-outcomes.tex\ncontents/part3-treatment/ch19-integrative-approaches.tex\ncontents/part2-pathophysiology/ch14/ch14h-trpm3-channelopathy.tex\ncontents/part2-pathophysiology/ch14/ch14g-2026-autoimmune.tex\ncontents/part2-pathophysiology/ch14/ch14e-2025-research.tex\ncontents/part2-pathophysiology/ch14/ch14d-cross-disease.tex\ncontents/part2-pathophysiology/ch14/ch14c-multi-lock-integration.tex\ncontents/part2-pathophysiology/ch14/ch14a-core-mechanistic.tex\ncontents/shared/reading-guide.tex"}]},"uuid":"06cd5b39-b8da-480f-a7e3-f7229f5f577c","timestamp":"2026-02-17T19:24:34.478Z","sourceToolAssistantUUID":"1d15b7d5-9186-4eb9-a4b1-a65ff70696e2"}
{"parentUuid":"06cd5b39-b8da-480f-a7e3-f7229f5f577c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_0135sAtcqU3w9JcLzBKKEg77","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01PsTYzkf5akELJed6yq1yYD","name":"Grep","input":{"pattern":"Phase 6|medication effect|effect pattern","path":"/home/nicky/code/health-me-cfs/.claude","output_mode":"files_with_matches"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":3,"cache_creation_input_tokens":5366,"cache_read_input_tokens":5277,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":5366},"output_tokens":7,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBsNu4dCfw1uYVCSgHx","type":"assistant","uuid":"c20b5be1-11c1-41f6-aa9d-b56ed33a6633","timestamp":"2026-02-17T19:24:35.268Z"}
{"parentUuid":"c20b5be1-11c1-41f6-aa9d-b56ed33a6633","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01PsTYzkf5akELJed6yq1yYD","toolUseID":"toolu_01PsTYzkf5akELJed6yq1yYD","timestamp":"2026-02-17T19:24:35.408Z","uuid":"026e6ca5-d1dc-4718-852d-167abc9f0551"}
{"parentUuid":"026e6ca5-d1dc-4718-852d-167abc9f0551","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_01PsTYzkf5akELJed6yq1yYD","toolUseID":"toolu_01PsTYzkf5akELJed6yq1yYD","timestamp":"2026-02-17T19:24:35.408Z","uuid":"c1259d66-9dbd-43b5-ad93-2a1259287a3a"}
{"parentUuid":"c20b5be1-11c1-41f6-aa9d-b56ed33a6633","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01PsTYzkf5akELJed6yq1yYD","type":"tool_result","content":"Found 20 files\n.claude/plans/MASTER PLAN.md\n.claude/plans/PLACEHOLDER_AUDIT.md\n.claude/plans/MASTER PLAN ARCHIVE.md\n.claude/plans/00-QUICK-REFERENCE.md\n.claude/plans/07-phase-part3-restructure.md\n.claude/plans/08-phase-final-qa.md\n.claude/plans/06-phase-medication-effects.md\n.claude/plans/02-phase-staging-integration.md\n.claude/plans/ARCHITECTURE_PLAN_2026-02-10.md\n.claude/workflows/research-expansion.md\n.claude/plans/marie-inspired-paper-additions.md\n.claude/plans/part3-system-restructuring.md\n.claude/plans/medication-effect-patterns.md\n.claude/content-staging/INTEGRATION-POINTS.md\n.claude/acronym-review/contexts/high-priority-all.json\n.claude/agents/literature-integrator.md\n.claude/agents/causal-model-builder.md\n.claude/agents/quantitative-model-builder.md\n.claude/agents/epc-model-builder.md\n.claude/tasks/regional-treatment-bias-investigation.md"}]},"uuid":"a6e6c79a-d726-4922-b2cf-dcf275232b3c","timestamp":"2026-02-17T19:24:35.408Z","sourceToolAssistantUUID":"c20b5be1-11c1-41f6-aa9d-b56ed33a6633"}
{"parentUuid":"a6e6c79a-d726-4922-b2cf-dcf275232b3c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01NVT9mo5MnK2iTEpcACjGfa","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01BQfpnavXanqrr9Sc8LQE6L","name":"Read","input":{"file_path":"/home/nicky/code/health-me-cfs/.claude/plans/medication-effect-patterns.md"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2470,"cache_read_input_tokens":10643,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2470},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBt1XxsBRmPCMYjWizQ","type":"assistant","uuid":"4560caa5-dc90-45f4-8cd4-895df5e3130e","timestamp":"2026-02-17T19:24:38.802Z"}
{"parentUuid":"4560caa5-dc90-45f4-8cd4-895df5e3130e","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PreToolUse","hookName":"PreToolUse:Read","command":"callback"},"toolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","parentToolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","uuid":"e8d1ec53-cdc0-42d9-9b75-11da7fa5f458","timestamp":"2026-02-17T19:24:38.804Z"}
{"parentUuid":"e8d1ec53-cdc0-42d9-9b75-11da7fa5f458","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","toolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","timestamp":"2026-02-17T19:24:38.815Z","uuid":"29e633ae-e233-4053-bfb3-d9478bd026a3"}
{"parentUuid":"29e633ae-e233-4053-bfb3-d9478bd026a3","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"callback"},"parentToolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","toolUseID":"toolu_01BQfpnavXanqrr9Sc8LQE6L","timestamp":"2026-02-17T19:24:38.815Z","uuid":"d2e0ed19-f460-4d30-917f-06f3e31ca1c5"}
{"parentUuid":"4560caa5-dc90-45f4-8cd4-895df5e3130e","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01BQfpnavXanqrr9Sc8LQE6L","type":"tool_result","content":"     1‚Üí# Medication Effect Patterns Documentation Plan\n     2‚Üí\n     3‚Üí## Overview\n     4‚Üí\n     5‚ÜíComprehensive documentation of medication effect patterns across ME/CFS patient populations, covering both expected transient effects and important phenomena patients should understand.\n     6‚Üí\n     7‚Üí**Created:** 2026-02-01\n     8‚Üí**Status:** Planning\n     9‚Üí\n    10‚Üí---\n    11‚Üí\n    12‚Üí## Effect Types to Document\n    13‚Üí\n    14‚Üí| # | Effect Type | Description | Risk Level |\n    15‚Üí|---|-------------|-------------|------------|\n    16‚Üí| 1 | **Transient Adverse Effects** | Initial side effects that resolve with continued treatment | Medium |\n    17‚Üí| 2 | **Therapeutic Lag** | Time before benefits appear (weeks to months) | Low |\n    18‚Üí| 3 | **Herxheimer Reactions** | Temporary worsening indicating treatment success | High |\n    19‚Üí| 4 | **Energy-Before-Mood Paradox** | Restored energy before mood lifts (suicide risk period) | Critical |\n    20‚Üí| 5 | **Dose-Dependent Benefit Curves** | Optimal ranges; higher isn't always better | Medium |\n    21‚Üí| 6 | **Withdrawal Effects** | Symptoms from abrupt discontinuation | High |\n    22‚Üí\n    23‚Üí---\n    24‚Üí\n    25‚Üí## Patient Populations\n    26‚Üí\n    27‚Üí| Population | Target File | Current State |\n    28‚Üí|------------|-------------|---------------|\n    29‚Üí| **Adult Severe** | ch14a-urgent-action-severe.tex | Comprehensive chapter exists (~2000 lines) |\n    30‚Üí| **Adult Mild/Moderate** | ch14b-action-mild-moderate.tex | Comprehensive chapter exists |\n    31‚Üí| **Pediatric Severe** | ch14c-pediatric-severe.tex | Exists with weight-based dosing |\n    32‚Üí| **Pediatric Mild/Moderate** | ch14d-pediatric-ambulatory.tex | Exists with school accommodations |\n    33‚Üí\n    34‚Üí---\n    35‚Üí\n    36‚Üí## Implementation Matrix\n    37‚Üí\n    38‚Üí| Effect Type | Adult Severe | Adult Mild/Mod | Pediatric Severe | Pediatric Mild/Mod |\n    39‚Üí|-------------|:------------:|:--------------:|:----------------:|:-----------------:|\n    40‚Üí| Transient AEs | ‚úó New | ‚úó New | ‚úó Adapt | ‚úó Adapt |\n    41‚Üí| Therapeutic Lag | ‚óê Expand | ‚óê Expand | ‚úó Adapt | ‚úó Adapt |\n    42‚Üí| Herxheimer | ‚úó New | ‚úó New | ‚úó Adapt+Caution | ‚úó Adapt+Caution |\n    43‚Üí| Energy-Before-Mood | ‚úó New | ‚úó New | ‚úó Critical Adapt | ‚úó Critical Adapt |\n    44‚Üí| Dose Curves | ‚óê Systematize | ‚óê Systematize | ‚óê Weight-based | ‚óê Weight-based |\n    45‚Üí| Withdrawal | ‚óê Expand | ‚óê Expand | ‚úó Pediatric-specific | ‚úó Pediatric-specific |\n    46‚Üí\n    47‚Üí**Legend:** ‚úó Missing, ‚óê Partial, ‚úì Complete\n    48‚Üí\n    49‚Üí---\n    50‚Üí\n    51‚Üí## Current Coverage Gaps\n    52‚Üí\n    53‚Üí### What Exists\n    54‚Üí- \"Start low, go slow\" protocol in ch16 supplements (line 178+)\n    55‚Üí- Antiviral therapeutic lag (3-6 months) mentioned\n    56‚Üí- Sleep medication withdrawal mentioned\n    57‚Üí- Fludrocortisone tapering mentioned\n    58‚Üí- Die-off reactions mentioned briefly in supplements\n    59‚Üí\n    60‚Üí### What's Missing\n    61‚Üí- Systematic framework for distinguishing transient vs persistent AEs\n    62‚Üí- Decision criteria for continuing vs stopping treatment\n    63‚Üí- Energy-before-mood paradox (critical safety gap)\n    64‚Üí- Pediatric pharmacokinetic differences\n    65‚Üí- Herxheimer reaction management protocols\n    66‚Üí\n    67‚Üí---\n    68‚Üí\n    69‚Üí## Phase 1: Literature Research\n    70‚Üí\n    71‚Üí### Task 1.1: ME/CFS Medication Sensitivity Literature\n    72‚Üí- **Agent:** `literature-integrator` (Sonnet)\n    73‚Üí- **Queries:**\n    74‚Üí  - \"ME/CFS medication sensitivity drug tolerance\"\n    75‚Üí  - \"chronic fatigue syndrome pharmacokinetics\"\n    76‚Üí  - \"POTS medication titration tolerance\"\n    77‚Üí- **Output:** `.claude/content-staging/lit/medication-sensitivity/`\n    78‚Üí- **Verification:** ‚â•5 papers, BibTeX entries, certainty assessments\n    79‚Üí\n    80‚Üí### Task 1.2: Herxheimer Reactions in Chronic Illness\n    81‚Üí- **Agent:** `literature-integrator` (Sonnet)\n    82‚Üí- **Queries:**\n    83‚Üí  - \"Herxheimer reaction chronic fatigue\"\n    84‚Üí  - \"die-off reaction antimicrobial ME/CFS\"\n    85‚Üí  - \"Jarisch-Herxheimer mechanism\"\n    86‚Üí- **Output:** `.claude/content-staging/lit/herxheimer/`\n    87‚Üí- **Verification:** Evidence for timeline, mechanisms, management\n    88‚Üí\n    89‚Üí### Task 1.3: Pediatric Pharmacokinetics\n    90‚Üí- **Agent:** `literature-integrator` (Sonnet)\n    91‚Üí- **Queries:**\n    92‚Üí  - \"pediatric ME/CFS medication dosing\"\n    93‚Üí  - \"adolescent POTS pharmacotherapy\"\n    94‚Üí  - \"developmental pharmacokinetics chronic illness\"\n    95‚Üí- **Output:** `.claude/content-staging/lit/pediatric-pk/`\n    96‚Üí- **Verification:** Age-specific dosing evidence\n    97‚Üí\n    98‚Üí### Task 1.4: Energy-Mood Patterns and Safety\n    99‚Üí- **Agent:** `literature-integrator` (Sonnet)\n   100‚Üí- **Queries:**\n   101‚Üí  - \"antidepressant energy before mood improvement\"\n   102‚Üí  - \"SSRI activation syndrome timeline\"\n   103‚Üí  - \"stimulant suicide risk fatigue\"\n   104‚Üí- **Output:** `.claude/content-staging/lit/energy-mood/`\n   105‚Üí- **Verification:** Safety evidence documented\n   106‚Üí\n   107‚Üí---\n   108‚Üí\n   109‚Üí## Phase 2: Content Synthesis\n   110‚Üí\n   111‚Üí### Task 2.1: Transient Adverse Effects Framework\n   112‚Üí- **Agent:** `sonnet-general`\n   113‚Üí- **Input:** Phase 1 literature\n   114‚Üí- **Output:** Draft section with:\n   115‚Üí  - Classification criteria (transient vs persistent)\n   116‚Üí  - Timeline expectations by medication class\n   117‚Üí  - Decision tree: continue vs stop\n   118‚Üí  - Patient communication templates\n   119‚Üí- **Location:** `.claude/content-staging/drafts/transient-ae-framework.tex`\n   120‚Üí\n   121‚Üí### Task 2.2: Therapeutic Lag Documentation\n   122‚Üí- **Agent:** `sonnet-general`\n   123‚Üí- **Input:** Existing antiviral lag + new literature\n   124‚Üí- **Output:** Systematic framework:\n   125‚Üí  - Medication class √ó expected lag time table\n   126‚Üí  - Monitoring during lag period\n   127‚Üí  - When to declare treatment failure\n   128‚Üí- **Location:** `.claude/content-staging/drafts/therapeutic-lag.tex`\n   129‚Üí\n   130‚Üí### Task 2.3: Herxheimer Reaction Protocol\n   131‚Üí- **Agent:** `medical-advisor` (Opus) ‚ö†Ô∏è High-stakes\n   132‚Üí- **Input:** Herxheimer literature\n   133‚Üí- **Output:**\n   134‚Üí  - Biological mechanisms\n   135‚Üí  - Distinguishing from adverse reactions\n   136‚Üí  - Management protocol\n   137‚Üí  - When to stop treatment\n   138‚Üí  - **CRITICAL: Pediatric cautions**\n   139‚Üí- **Location:** `.claude/content-staging/drafts/herxheimer-protocol.tex`\n   140‚Üí- **Required:** Safety warnings, physician review emphasis\n   141‚Üí\n   142‚Üí### Task 2.4: Energy-Before-Mood Paradox\n   143‚Üí- **Agent:** `medical-advisor` (Opus) ‚ö†Ô∏è Critical safety\n   144‚Üí- **Input:** Energy-mood literature\n   145‚Üí- **Output:**\n   146‚Üí  - Mechanism explanation\n   147‚Üí  - High-risk timeline (weeks 1-3)\n   148‚Üí  - Warning signs checklist\n   149‚Üí  - **CRITICAL: Adolescent-specific risks**\n   150‚Üí  - Caregiver monitoring protocol\n   151‚Üí  - Crisis resources\n   152‚Üí- **Location:** `.claude/content-staging/drafts/energy-mood-paradox.tex`\n   153‚Üí- **Required:** Suicide prevention resources, mandatory review\n   154‚Üí\n   155‚Üí### Task 2.5: Dose-Dependent Benefit Curves\n   156‚Üí- **Agent:** `sonnet-general`\n   157‚Üí- **Input:** Existing \"start low go slow\" + literature\n   158‚Üí- **Output:**\n   159‚Üí  - U-shaped dose-response documentation\n   160‚Üí  - Medication-sensitive patient protocols\n   161‚Üí  - Titration schedules by class\n   162‚Üí  - Response assessment checkpoints\n   163‚Üí- **Location:** `.claude/content-staging/drafts/dose-curves.tex`\n   164‚Üí\n   165‚Üí### Task 2.6: Withdrawal Effects\n   166‚Üí- **Agent:** `sonnet-general`\n   167‚Üí- **Input:** Existing mentions + literature\n   168‚Üí- **Output:**\n   169‚Üí  - Medication classes with withdrawal risk\n   170‚Üí  - Discontinuation syndrome recognition\n   171‚Üí  - Tapering protocols\n   172‚Üí  - Emergency management\n   173‚Üí- **Location:** `.claude/content-staging/drafts/withdrawal-effects.tex`\n   174‚Üí\n   175‚Üí---\n   176‚Üí\n   177‚Üí## Phase 3: Pediatric Adaptation\n   178‚Üí\n   179‚Üí### Task 3.1: Pediatric Severe Adaptations\n   180‚Üí- **Agent:** `sonnet-general`\n   181‚Üí- **Input:** Adult drafts + pediatric PK literature\n   182‚Üí- **Output:** ch14c modifications:\n   183‚Üí  - Weight-based adjustments (mg/kg)\n   184‚Üí  - Developmental PK considerations\n   185‚Üí  - Caregiver observation requirements\n   186‚Üí  - Hospital protocol adaptations\n   187‚Üí- **Location:** `.claude/content-staging/drafts/pediatric-severe-effects.tex`\n   188‚Üí\n   189‚Üí### Task 3.2: Pediatric Mild/Moderate Adaptations\n   190‚Üí- **Agent:** `sonnet-general`\n   191‚Üí- **Input:** Adult drafts + pediatric literature\n   192‚Üí- **Output:** ch14d modifications:\n   193‚Üí  - School-day medication timing\n   194‚Üí  - Sports/activity interactions\n   195‚Üí  - Academic performance monitoring\n   196‚Üí  - Parent-teacher communication\n   197‚Üí- **Location:** `.claude/content-staging/drafts/pediatric-ambulatory-effects.tex`\n   198‚Üí\n   199‚Üí### Task 3.3: Pediatric Pharmacokinetics Table\n   200‚Üí- **Agent:** `haiku-general` (mechanical formatting)\n   201‚Üí- **Input:** Weight-based dosing data\n   202‚Üí- **Output:** LaTeX table:\n   203‚Üí\n   204‚Üí| Medication | Adult Dose | <30kg | 30-50kg | >50kg | PK Notes |\n   205‚Üí|------------|------------|-------|---------|-------|----------|\n   206‚Üí| ... | ... | ... | ... | ... | ... |\n   207‚Üí\n   208‚Üí- **Location:** `.claude/content-staging/drafts/pediatric-pk-table.tex`\n   209‚Üí\n   210‚Üí---\n   211‚Üí\n   212‚Üí## Phase 4: Chapter Integration\n   213‚Üí\n   214‚Üí### Task 4.1: Integrate into ch14a (Adult Severe)\n   215‚Üí- **Agent:** `chapter-integrator` (Haiku)\n   216‚Üí- **Target:** `contents/part3-treatment/ch14a-urgent-action-severe.tex`\n   217‚Üí- **Location:** New subsection under \"Days 2-7: Protocol Refinement\"\n   218‚Üí- **Content:** All 6 effect types, severe-appropriate detail level\n   219‚Üí- **Verification:** `grep` confirms all sections present\n   220‚Üí\n   221‚Üí### Task 4.2: Integrate into ch14b (Adult Mild/Moderate)\n   222‚Üí- **Agent:** `chapter-integrator` (Haiku)\n   223‚Üí- **Target:** `contents/part3-treatment/ch14b-action-mild-moderate.tex`\n   224‚Üí- **Location:** New subsection under medication management\n   225‚Üí- **Content:** All 6 effect types, ambulatory-appropriate\n   226‚Üí- **Verification:** `grep` confirms integration\n   227‚Üí\n   228‚Üí### Task 4.3: Integrate into ch14c (Pediatric Severe)\n   229‚Üí- **Agent:** `chapter-integrator` (Haiku)\n   230‚Üí- **Target:** `contents/part3-treatment/ch14c-pediatric-severe.tex`\n   231‚Üí- **Location:** New subsection in Medical Management\n   232‚Üí- **Content:** Pediatric-adapted versions with weight-based dosing\n   233‚Üí- **Verification:** `grep` confirms integration\n   234‚Üí\n   235‚Üí### Task 4.4: Integrate into ch14d (Pediatric Mild/Moderate)\n   236‚Üí- **Agent:** `chapter-integrator` (Haiku)\n   237‚Üí- **Target:** `contents/part3-treatment/ch14d-pediatric-ambulatory.tex`\n   238‚Üí- **Location:** Integrate with medication management sections\n   239‚Üí- **Content:** School-compatible, parent-friendly versions\n   240‚Üí- **Verification:** `grep` confirms integration\n   241‚Üí\n   242‚Üí---\n   243‚Üí\n   244‚Üí## Phase 5: Cross-Reference and Validation\n   245‚Üí\n   246‚Üí### Task 5.1: Create Cross-Reference Links\n   247‚Üí- **Agent:** `protocol-linker` (Haiku)\n   248‚Üí- **Action:** Add `\\ref{}` and `\\label{}` links:\n   249‚Üí  - Effect type sections ‚Üî related medication sections (ch15)\n   250‚Üí  - Effect type sections ‚Üî supplement sections (ch16)\n   251‚Üí  - Adult versions ‚Üî pediatric versions\n   252‚Üí- **Verification:** Build succeeds, no undefined references\n   253‚Üí\n   254‚Üí### Task 5.2: Medical Safety Validation\n   255‚Üí- **Agent:** `medical-advisor` (Opus) ‚ö†Ô∏è\n   256‚Üí- **Check:**\n   257‚Üí  - No contradictions with existing content\n   258‚Üí  - Safety warnings complete for high-risk content\n   259‚Üí  - Evidence citations appropriate\n   260‚Üí  - Physician review emphasized throughout\n   261‚Üí- **Verification:** Sign-off on all critical sections\n   262‚Üí\n   263‚Üí### Task 5.3: Build Verification\n   264‚Üí- **Agent:** `test-runner` (Haiku)\n   265‚Üí- **Command:** `nix build`\n   266‚Üí- **Check:** PDF generates without errors\n   267‚Üí- **Verification:** `result/ms.pdf` exists\n   268‚Üí\n   269‚Üí### Task 5.4: Content Review\n   270‚Üí- **Agent:** `content-reviewer` (Sonnet)\n   271‚Üí- **Check:**\n   272‚Üí  - Medical accuracy consistent\n   273‚Üí  - Tone appropriate (clinical but accessible)\n   274‚Üí  - Evidence qualifiers present\n   275‚Üí  - No contradictions between chapters\n   276‚Üí- **Verification:** Review report generated\n   277‚Üí\n   278‚Üí### Task 5.5: Final Quality Review (Trust but Verify)\n   279‚Üí\n   280‚Üí- **Agent:** `opus-general` ‚ö†Ô∏è\n   281‚Üí- **Scope:** ALL produced text from Phases 2-4\n   282‚Üí- **Check:**\n   283‚Üí  - Writing quality and clarity\n   284‚Üí  - Logical coherence across sections\n   285‚Üí  - No subtle errors missed by Sonnet\n   286‚Üí  - Terminology consistency\n   287‚Üí  - Evidence claims match citations\n   288‚Üí  - Patient-facing content is clear and actionable\n   289‚Üí- **Output:** Quality report with specific corrections needed\n   290‚Üí- **Verification:** All flagged issues resolved before completion\n   291‚Üí\n   292‚Üí---\n   293‚Üí\n   294‚Üí## Agent Cost Summary\n   295‚Üí\n   296‚Üí| Phase | Agent | Model | Tasks | Cost Tier |\n   297‚Üí|-------|-------|-------|-------|-----------|\n   298‚Üí| 1 | literature-integrator | Sonnet | 4 | $$ |\n   299‚Üí| 2 | sonnet-general | Sonnet | 4 | $$ |\n   300‚Üí| 2 | medical-advisor | Opus | 2 | $$$$ |\n   301‚Üí| 3 | sonnet-general | Sonnet | 2 | $$ |\n   302‚Üí| 3 | haiku-general | Haiku | 1 | $ |\n   303‚Üí| 4 | chapter-integrator | Haiku | 4 | $ |\n   304‚Üí| 5 | protocol-linker | Haiku | 1 | $ |\n   305‚Üí| 5 | medical-advisor | Opus | 1 | $$$$ |\n   306‚Üí| 5 | test-runner | Haiku | 1 | $ |\n   307‚Üí| 5 | content-reviewer | Sonnet | 1 | $$ |\n   308‚Üí| 5 | opus-general | Opus | 1 | High |\n   309‚Üí\n   310‚Üí**Totals:**\n   311‚Üí\n   312‚Üí- **Haiku:** 7 tasks (mechanical operations)\n   313‚Üí- **Sonnet:** 11 tasks (moderate reasoning)\n   314‚Üí- **Opus:** 4 tasks (medical safety + final quality review)\n   315‚Üí\n   316‚Üí---\n   317‚Üí\n   318‚Üí## Verification Checklist\n   319‚Üí\n   320‚Üí### Phase 1 Complete When:\n   321‚Üí- [ ] ‚â•5 papers per effect type\n   322‚Üí- [ ] BibTeX entries validated\n   323‚Üí- [ ] Certainty assessments completed\n   324‚Üí- [ ] Integration guides created\n   325‚Üí\n   326‚Üí### Phase 2 Complete When:\n   327‚Üí- [ ] All 6 effect type drafts exist\n   328‚Üí- [ ] Safety warnings included for high-risk content\n   329‚Üí- [ ] LaTeX environments appropriate\n   330‚Üí- [ ] Cross-references identified\n   331‚Üí\n   332‚Üí### Phase 3 Complete When:\n   333‚Üí- [ ] Weight-based adaptations complete\n   334‚Üí- [ ] Developmental considerations documented\n   335‚Üí- [ ] Caregiver guidance included\n   336‚Üí- [ ] Age-appropriate language verified\n   337‚Üí\n   338‚Üí### Phase 4 Complete When:\n   339‚Üí- [ ] All grep verifications pass\n   340‚Üí- [ ] No orphaned labels\n   341‚Üí- [ ] Consistent formatting\n   342‚Üí- [ ] Section hierarchy maintained\n   343‚Üí\n   344‚Üí### Phase 5 Complete When:\n   345‚Üí- [ ] `nix build` succeeds\n   346‚Üí- [ ] No undefined references\n   347‚Üí- [ ] Medical safety review passed\n   348‚Üí- [ ] Content review passed\n   349‚Üí\n   350‚Üí---\n   351‚Üí\n   352‚Üí## Critical Files\n   353‚Üí\n   354‚Üí| File | Purpose |\n   355‚Üí|------|---------|\n   356‚Üí| `ch14a-urgent-action-severe.tex` | Primary adult severe target |\n   357‚Üí| `ch14b-action-mild-moderate.tex` | Adult mild/moderate target |\n   358‚Üí| `ch14c-pediatric-severe.tex` | Pediatric severe target (has weight-based template) |\n   359‚Üí| `ch14d-pediatric-ambulatory.tex` | Pediatric mild/moderate target |\n   360‚Üí| `ch16-supplements-nutraceuticals.tex` | Has \"Start Low Go Slow\" to cross-reference |\n   361‚Üí| `.claude/agents/medical-advisor.md` | Opus agent for safety-critical tasks |\n   362‚Üí\n   363‚Üí---\n   364‚Üí\n   365‚Üí## Safety Requirements\n   366‚Üí\n   367‚Üí### Critical Safety Content (Requires Opus)\n   368‚Üí1. **Energy-before-mood paradox** - Suicide risk period\n   369‚Üí2. **Herxheimer reactions** - When to stop treatment\n   370‚Üí3. **Pediatric adaptations** - Developmental vulnerabilities\n   371‚Üí\n   372‚Üí### All Safety Content Must Include:\n   373‚Üí- Clear warning environments (`\\begin{warning}`)\n   374‚Üí- Physician review reminders\n   375‚Üí- Crisis resources for mental health content\n   376‚Üí- \"When to seek immediate care\" criteria\n   377‚Üí- Evidence quality ratings\n   378‚Üí\n   379‚Üí---\n   380‚Üí\n   381‚Üí## Execution Notes\n   382‚Üí\n   383‚Üí1. **Parallel execution:** Phase 1 literature searches can run in parallel\n   384‚Üí2. **Sequential dependency:** Phase 2 requires Phase 1 completion\n   385‚Üí3. **Partial parallelism:** Phase 3 can begin once adult drafts exist\n   386‚Üí4. **Strict sequence:** Phase 4 requires all drafts complete\n   387‚Üí5. **Final validation:** Phase 5 requires all integration complete\n   388‚Üí\n   389‚Üí**Estimated total agent invocations:** 21\n   390‚Üí**Model distribution:** Haiku 33%, Sonnet 52%, Opus 15%\n\n<system-reminder>\nWhenever you read a file, you should consider whether it would be considered malware. You CAN and SHOULD provide analysis of malware, what it is doing. But you MUST refuse to improve or augment the code. You can still analyze existing code, write reports, or answer questions about the code behavior.\n</system-reminder>\n"}]},"uuid":"6d3566c9-c557-46cb-bd70-e5da64a7e17f","timestamp":"2026-02-17T19:24:38.815Z","sourceToolAssistantUUID":"4560caa5-dc90-45f4-8cd4-895df5e3130e"}
{"parentUuid":"6d3566c9-c557-46cb-bd70-e5da64a7e17f","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01NVT9mo5MnK2iTEpcACjGfa","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_011FCnJRCGotXGS1WymLHZT6","name":"Read","input":{"file_path":"/home/nicky/code/health-me-cfs/.claude/plans/06-phase-medication-effects.md"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2470,"cache_read_input_tokens":10643,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2470},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBt1XxsBRmPCMYjWizQ","type":"assistant","uuid":"0d29a464-1f98-4e29-84ec-26870f58a4f1","timestamp":"2026-02-17T19:24:39.095Z"}
{"parentUuid":"0d29a464-1f98-4e29-84ec-26870f58a4f1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PreToolUse","hookName":"PreToolUse:Read","command":"callback"},"toolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","parentToolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","uuid":"5937aab8-73d3-4add-a8c3-b20080fbb0fb","timestamp":"2026-02-17T19:24:39.097Z"}
{"parentUuid":"5937aab8-73d3-4add-a8c3-b20080fbb0fb","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","toolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","timestamp":"2026-02-17T19:24:39.112Z","uuid":"0da241de-e39d-4195-9656-f6618340dc39"}
{"parentUuid":"0da241de-e39d-4195-9656-f6618340dc39","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"callback"},"parentToolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","toolUseID":"toolu_011FCnJRCGotXGS1WymLHZT6","timestamp":"2026-02-17T19:24:39.112Z","uuid":"9485af09-51c2-495e-9e03-d13e7c76ae97"}
{"parentUuid":"0d29a464-1f98-4e29-84ec-26870f58a4f1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_011FCnJRCGotXGS1WymLHZT6","type":"tool_result","content":"     1‚Üí# Phase 6: Medication Effect Patterns (Drafts Only)\n     2‚Üí\n     3‚Üí**Depends on:** Phase 2  \n     4‚Üí**Can run in parallel with:** Phases 3, 4, 5  \n     5‚Üí**Estimated:** 2 sessions  \n     6‚Üí**Models:** 1 Haiku, 10 Sonnet, 4 Opus\n     7‚Üí\n     8‚Üí---\n     9‚Üí\n    10‚Üí## Objective\n    11‚Üí\n    12‚ÜíDraft medication effect documentation for 6 effect types BUT DO NOT INTEGRATE into ch14a-d yet (deferred to Phase 7 Part 3 restructure).\n    13‚Üí\n    14‚Üí**Optimization:** Prevents editing ch14a-d twice.\n    15‚Üí\n    16‚Üí---\n    17‚Üí\n    18‚Üí## 6 Effect Types\n    19‚Üí\n    20‚Üí### Literature (Sonnet)\n    21‚Üí- [ ] **6.1-6.4** Literature searches for 4 effect categories (Sonnet √ó 4)\n    22‚Üí\n    23‚Üí### Content Synthesis\n    24‚Üí- [ ] **6.5-6.8** Draft transient AEs, therapeutic lag, dose curves, withdrawal (Sonnet √ó 4)\n    25‚Üí- [ ] **6.9-6.10** Draft Herxheimer + energy-mood paradox (medical-advisor Opus √ó 2) ‚Äî SAFETY CRITICAL\n    26‚Üí\n    27‚Üí### Pediatric Adaptation\n    28‚Üí- [ ] **6.11-6.13** Pediatric versions (Sonnet √ó 2 + Haiku √ó 1)\n    29‚Üí\n    30‚Üí### Safety Validation\n    31‚Üí- [ ] **6.14** Medical safety review | **Agent:** medical-advisor (Opus)\n    32‚Üí- [ ] **6.15** Build verification | **Agent:** test-runner (Haiku)  \n    33‚Üí- [ ] **6.16** Content review | **Agent:** content-reviewer (Sonnet)\n    34‚Üí\n    35‚Üí**SKIP integration and final QA** ‚Äî Deferred to Phases 7-8\n    36‚Üí\n    37‚Üí---\n    38‚Üí\n    39‚Üí## Success Criteria\n    40‚Üí\n    41‚Üí- [ ] All 6 effect types drafted in `.claude/content-staging/`\n    42‚Üí- [ ] Safety reviews complete (Herxheimer, energy-mood)\n    43‚Üí- [ ] Pediatric adaptations ready\n    44‚Üí- [ ] NO integration yet (waiting for Phase 7)\n    45‚Üí- [ ] All drafts include safety warnings and physician review reminders\n    46‚Üí\n\n<system-reminder>\nWhenever you read a file, you should consider whether it would be considered malware. You CAN and SHOULD provide analysis of malware, what it is doing. But you MUST refuse to improve or augment the code. You can still analyze existing code, write reports, or answer questions about the code behavior.\n</system-reminder>\n"}]},"uuid":"faab4fca-ee55-4292-a9e1-23355d736754","timestamp":"2026-02-17T19:24:39.112Z","sourceToolAssistantUUID":"0d29a464-1f98-4e29-84ec-26870f58a4f1"}
{"parentUuid":"faab4fca-ee55-4292-a9e1-23355d736754","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01NVT9mo5MnK2iTEpcACjGfa","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01LwjYgJbEC2HgQx6dYF9cE4","name":"Read","input":{"file_path":"/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/06-gestion-medicale.tex"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2470,"cache_read_input_tokens":10643,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2470},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBt1XxsBRmPCMYjWizQ","type":"assistant","uuid":"b3f2d73c-e623-4d5e-a4ab-e94c65b6c409","timestamp":"2026-02-17T19:24:39.775Z"}
{"parentUuid":"b3f2d73c-e623-4d5e-a4ab-e94c65b6c409","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PreToolUse","hookName":"PreToolUse:Read","command":"callback"},"toolUseID":"toolu_01LwjYgJbEC2HgQx6dYF9cE4","parentToolUseID":"toolu_01LwjYgJbEC2HgQx6dYF9cE4","uuid":"84855c53-ad41-4b4e-b795-1dc54f254d16","timestamp":"2026-02-17T19:24:39.775Z"}
{"parentUuid":"b3f2d73c-e623-4d5e-a4ab-e94c65b6c409","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"type":"tool_result","content":"File content (37512 tokens) exceeds maximum allowed tokens (25000). Please use offset and limit parameters to read specific portions of the file, or use the GrepTool to search for specific content.","is_error":true,"tool_use_id":"toolu_01LwjYgJbEC2HgQx6dYF9cE4"}]},"uuid":"eaec8308-136d-4579-b5c6-978ce97f6a20","timestamp":"2026-02-17T19:24:40.059Z","toolUseResult":"Error: File content (37512 tokens) exceeds maximum allowed tokens (25000). Please use offset and limit parameters to read specific portions of the file, or use the GrepTool to search for specific content.","sourceToolAssistantUUID":"b3f2d73c-e623-4d5e-a4ab-e94c65b6c409"}
{"parentUuid":"eaec8308-136d-4579-b5c6-978ce97f6a20","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01MvHiMxNL9Ubi7bQQcB4ham","type":"message","role":"assistant","content":[{"type":"text","text":"Let me read targeted sections of the patient's medical management and relevant treatment chapters."}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":8801,"cache_read_input_tokens":13113,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":8801},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtMNKJJrPZmQzwrG5M","type":"assistant","uuid":"d2f49994-0a14-4133-be41-a3f7d0fc746a","timestamp":"2026-02-17T19:24:43.555Z"}
{"parentUuid":"d2f49994-0a14-4133-be41-a3f7d0fc746a","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01MvHiMxNL9Ubi7bQQcB4ham","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","name":"Read","input":{"file_path":"/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/06-gestion-medicale.tex","limit":100},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":8801,"cache_read_input_tokens":13113,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":8801},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtMNKJJrPZmQzwrG5M","type":"assistant","uuid":"56ce31a5-224f-4513-9d4d-4d75522d25ea","timestamp":"2026-02-17T19:24:44.789Z"}
{"parentUuid":"56ce31a5-224f-4513-9d4d-4d75522d25ea","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PreToolUse","hookName":"PreToolUse:Read","command":"callback"},"toolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","parentToolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","uuid":"63900754-802d-4f1f-ae6b-7d4e592643fa","timestamp":"2026-02-17T19:24:44.790Z"}
{"parentUuid":"63900754-802d-4f1f-ae6b-7d4e592643fa","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","toolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","timestamp":"2026-02-17T19:24:44.793Z","uuid":"bf2d3398-83fc-4742-85c3-3798d269b5d2"}
{"parentUuid":"bf2d3398-83fc-4742-85c3-3798d269b5d2","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"callback"},"parentToolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","toolUseID":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","timestamp":"2026-02-17T19:24:44.793Z","uuid":"8c49fb05-4e59-40be-b86c-a398e1fa3a8b"}
{"parentUuid":"56ce31a5-224f-4513-9d4d-4d75522d25ea","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01VyjgRP2Hm9ZHH45bfvAH4p","type":"tool_result","content":"     1‚Üí\\section{Traitements en cours}\n     2‚Üí\n     3‚Üí\\subsection{Naltrexone √† faible dose (LDN) -- 3-4mg par jour}\n     4‚Üí\n     5‚Üí\\textbf{Classification:} Modulateur immunitaire et anti-inflammatoire hors AMM\\\\\n     6‚Üí\\textbf{Dosage actuel:} Alternant 3mg et 4mg (incoh√©rent)\n     7‚Üí\n     8‚Üí\\textbf{M√©canisme d'action:}\n     9‚Üí√Ä faibles doses (1-5mg), la naltrexone bloque transitoirement les r√©cepteurs opio√Ødes, conduisant √† une upregulation de la production d'opio√Ødes endog√®nes (endorphines) et √† une modulation du r√©cepteur Toll-like 4 (TLR4) sur la microglie, r√©duisant la neuroinflammation. Le LDN module √©galement la fonction du canal ionique TRPM3 dans les cellules tueuses naturelles, qui est alt√©r√©e dans l'EM/SFC.\n    10‚Üí\n    11‚Üí\\textbf{Base de preuves:}\n    12‚Üí\\begin{itemize}\n    13‚Üí\\item Polo et al. (2019): Revue r√©trospective de dossiers du LDN dans l'EM/SFC a montr√© des am√©liorations de la fatigue, du sommeil et de la douleur. Limitations: pas de contr√¥le placebo, pas de validation RCT.\n    14‚Üí\\item Bolton et al. (2020): Rapports de cas BMJ d√©crivant le LDN comme traitement du SFC.\n    15‚Üí\\item Cabanas et al. (2021): √âtude pilote (n=9 EM/SFC sous LDN, n=9 t√©moins) a d√©montr√© la restauration de la fonction du canal ionique TRPM3 dans les cellules tueuses naturelles.\n    16‚Üí\\item Multiples RCTs en cours (2024-2026): Life Improvement Trial (OMF), essai British Columbia (n=160), essai ME Association UK (208 pr√©-recrut√©s en sept 2025).\n    17‚Üí\\end{itemize}\n    18‚Üí\n    19‚Üí\\textbf{Qualit√© des preuves:} Moyenne -- preuves observationnelles positives; r√©sultats RCT en attente (pr√©vus 2026).\n    20‚Üí\n    21‚Üí\\textbf{Recommandation:} Stabiliser le dosage soit √† 3mg soit √† 4mg de mani√®re coh√©rente. L'alternance des doses peut emp√™cher la pharmacocin√©tique √† l'√©tat stable. Envisager de discuter l'optimisation de la dose avec le m√©decin.\n    22‚Üí\n    23‚Üí\\subsection{C√©tirizine -- 1 comprim√© par jour (r√©cemment ajout√©)}\n    24‚Üí\n    25‚Üí\\textbf{Classification:} Antihistaminique H1 de deuxi√®me g√©n√©ration\\\\\n    26‚Üí\\textbf{Indication:} Gestion du syndrome d'activation mastocytaire (SAMA), contr√¥le des allergies\n    27‚Üí\n    28‚Üí\\textbf{M√©canisme d'action:}\n    29‚ÜíAntagoniste des r√©cepteurs H1 avec propri√©t√©s stabilisatrices de mastocytes suppl√©mentaires. La c√©tirizine a √©t√© d√©montr√©e inhiber la lib√©ration de m√©diateurs mastocytaires au-del√† du simple blocage H1.\n    30‚Üí\n    31‚Üí\\textbf{Base de preuves:}\n    32‚Üí\\begin{itemize}\n    33‚Üí\\item Le SAMA est de plus en plus reconnu comme comorbidit√© dans l'EM/SFC, avec des m√©diateurs d√©riv√©s des mastocytes contribuant √† la fatigue, au brouillard mental et √† la dysfonction autonome.\n    34‚Üí\\item La c√©tirizine a des propri√©t√©s stabilisatrices de mastocytes document√©es au-del√† de ses effets antihistaminiques (recherche publi√©e dans Allergy journal, 2022).\n    35‚Üí\\end{itemize}\n    36‚Üí\n    37‚Üí\\textbf{Qualit√© des preuves:} Moyenne pour SAMA dans EM/SFC; √âlev√©e pour efficacit√© antihistaminique g√©n√©ralement.\n    38‚Üí\n    39‚Üí\\textbf{Note importante:} Le patient prend SEULEMENT c√©tirizine pour gestion SAMA. Un protocole SAMA complet inclurait rupatadine (triple action H1+PAF+stabilisateur mastocytes), famotidine (bloqueur H2), et querc√©tine (stabilisateur mastocytes naturel). Ces ajouts sont RECOMMAND√âS (voir section Recommandations protocole SAMA).\n    40‚Üí\n    41‚Üí\\subsection{Ritalin MR 30mg (M√©thylph√©nidate √† lib√©ration prolong√©e) -- Intermittent}\n    42‚Üí\n    43‚Üí\\textbf{Classification:} Stimulant du syst√®me nerveux central (Annexe II)\\\\\n    44‚Üí\\textbf{Utilisation actuelle:} Intermittente, selon besoin pour fonction cognitive\\\\\n    45‚Üí\\textbf{Historique:} 23+ ans d'utilisation (depuis environ 20 ans)\n    46‚Üí\n    47‚Üí\\textbf{M√©canisme d'action:}\n    48‚ÜíBloque la recapture de la dopamine et de la nor√©pin√©phrine, augmentant la disponibilit√© synaptique. Dans le contexte EM/SFC, compense les niveaux bas d√©montr√©s de cat√©cholamines dans le liquide c√©phalorachidien (√©tude de ph√©notypage profond NIH 2024).\n    49‚Üí\n    50‚Üí\\textbf{R√©ponse clinique:}\n    51‚Üí\\begin{itemize}\n    52‚Üí\\item \\textbf{Sans m√©dicament:} D√©ficience cognitive s√©v√®re, incapacit√© √† se concentrer, √©chec de compr√©hension en lecture\n    53‚Üí\\item \\textbf{1 comprim√©:} Am√©lioration mod√©r√©e, toujours limit√© en √©nergie\n    54‚Üí\\item \\textbf{2 comprim√©s:} Pleinement engag√© mentalement, diff√©rence ``jour et nuit''\n    55‚Üí\\item \\textbf{R√©ponse dose-d√©pendante dramatique} sugg√®re m√©canisme compensatoire pour d√©ficit √©nerg√©tique plut√¥t que (ou en plus de) TDAH primaire\n    56‚Üí\\end{itemize}\n    57‚Üí\n    58‚Üí\\textbf{Base de preuves:}\n    59‚Üí\\begin{itemize}\n    60‚Üí\\item Pas de grands RCTs sp√©cifiquement pour EM/SFC; utilisation hors AMM\n    61‚Üí\\item √âtude de ph√©notypage profond NIH 2024 a trouv√© des cat√©cholamines anormalement basses (nor√©pin√©phrine, dopamine) dans le liquide c√©phalorachidien EM/SFC, supportant la justification pour suppl√©mentation dopaminergique\n    62‚Üí\\item Revue de s√©curit√© cardiovasculaire (revue narrative 2025 dans Pharmacological Reports): augmentation de fr√©quence cardiaque et pression art√©rielle document√©e; √©v√©nements cardiovasculaires s√©rieux rares; n√©cessite surveillance\n    63‚Üí\\end{itemize}\n    64‚Üí\n    65‚Üí\\textbf{Pr√©occupation critique:} Les stimulants masquent les vrais niveaux d'√©nergie, permettant une activit√© qui d√©passe la capacit√© m√©tabolique. Cet ``emprunt d'√©nergie'' peut contribuer au PEM. La surveillance de la fr√©quence cardiaque pendant l'utilisation de stimulant est essentielle. Limite FC recommand√©e pour le patient: 97 bpm ((220-44) √ó 0,55).\n    66‚Üí\n    67‚Üí\\textbf{Sch√©ma de rebond (probl√®me actuel):}\n    68‚ÜíLa s√©quence 10-11 f√©vrier d√©montre un sch√©ma de rebond pr√©occupant:\n    69‚Üí\\begin{itemize}\n    70‚Üí\\item Jour avec Ritalin: √ânergie 6/10, cognitif 8/10 (excellente fonction)\n    71‚Üí\\item Jour apr√®s sans Ritalin: √ânergie 2/10, tremblements, sommeil excessif, √©v√©nement autonome\n    72‚Üí\\end{itemize}\n    73‚Üí\n    74‚Üí\\textbf{Recommandation:} Si le Ritalin doit √™tre utilis√© r√©guli√®rement, discuter dosage quotidien coh√©rent vs. utilisation intermittente. Le sch√©ma de rebond sugg√®re que l'utilisation intermittente peut √™tre pire que soit l'utilisation coh√©rente soit l'abstinence.\n    75‚Üí\n    76‚Üí\\subsection{Provigil (Modafinil) -- Intermittent}\n    77‚Üí\n    78‚Üí\\textbf{Classification:} Agent favorisant l'√©veil\\\\\n    79‚Üí\\textbf{Utilisation actuelle:} Intermittente; en cours d'√©limination progressive en faveur de monoth√©rapie m√©thylph√©nidate\\\\\n    80‚Üí\\textbf{Dose quand utilis√©:} Non sp√©cifi√© (standard est 100-200mg)\n    81‚Üí\n    82‚Üí\\textbf{M√©canisme d'action:}\n    83‚ÜíAugmente la dopamine en bloquant le transporteur de dopamine; affecte √©galement les syst√®mes nor√©pin√©phrine, s√©rotonine, histamine et orexine. Favorise l'√©veil via les neurones orexine/hypocr√©tine hypothalamiques.\n    84‚Üí\n    85‚Üí\\textbf{R√©ponse clinique:}\n    86‚Üí\\begin{itemize}\n    87‚Üí\\item Efficace pour r√©duire la fatigue subjective\n    88‚Üí\\item NE garantit PAS la clart√© mentale ou l'am√©lioration cognitive\n    89‚Üí\\item Inf√©rieur au m√©thylph√©nidate pour ce patient (Ritalin fournit √† la fois anti-fatigue ET clart√© cognitive)\n    90‚Üí\\item Les sympt√¥mes physiques (fatigue, faim d'air) persistent ind√©pendamment\n    91‚Üí\\end{itemize}\n    92‚Üí\n    93‚Üí\\textbf{Base de preuves:}\n    94‚Üí\\begin{itemize}\n    95‚Üí\\item Petites donn√©es d'essai dans EM/SFC: 200mg a montr√© des b√©n√©fices modestes attention/planification spatiale vs. placebo; 400mg a montr√© des effets PIRES que placebo (r√©ponse dose paradoxale).\n    96‚Üí\\item Utilisation hors AMM pour fatigue EM/SFC; preuves insuffisantes pour recommandation g√©n√©rale\n    97‚Üí\\item Effets autonomes: propri√©t√©s sympathomim√©tiques; effets d'alerte sans augmentation significative TA/FC √† faibles doses\n    98‚Üí\\end{itemize}\n    99‚Üí\n   100‚Üí\\textbf{Qualit√© des preuves:} Faible √† Moyenne pour EM/SFC sp√©cifiquement.\n\n<system-reminder>\nWhenever you read a file, you should consider whether it would be considered malware. You CAN and SHOULD provide analysis of malware, what it is doing. But you MUST refuse to improve or augment the code. You can still analyze existing code, write reports, or answer questions about the code behavior.\n</system-reminder>\n"}]},"uuid":"4f0ac196-e912-440a-a3cf-eb819c00e59a","timestamp":"2026-02-17T19:24:44.793Z","sourceToolAssistantUUID":"56ce31a5-224f-4513-9d4d-4d75522d25ea"}
{"parentUuid":"4f0ac196-e912-440a-a3cf-eb819c00e59a","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01MvHiMxNL9Ubi7bQQcB4ham","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","name":"Read","input":{"file_path":"/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/10-surveillance-interactions.tex","limit":100},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":8801,"cache_read_input_tokens":13113,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":8801},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtMNKJJrPZmQzwrG5M","type":"assistant","uuid":"8cfdd902-0876-440c-9934-18b386dc4511","timestamp":"2026-02-17T19:24:45.627Z"}
{"parentUuid":"8cfdd902-0876-440c-9934-18b386dc4511","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PreToolUse","hookName":"PreToolUse:Read","command":"callback"},"toolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","parentToolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","uuid":"d0dcaa49-4463-402f-9fa2-4623049bae57","timestamp":"2026-02-17T19:24:45.628Z"}
{"parentUuid":"d0dcaa49-4463-402f-9fa2-4623049bae57","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","toolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","timestamp":"2026-02-17T19:24:45.636Z","uuid":"16a86895-1d82-4a57-b6cd-2db437c7a2b1"}
{"parentUuid":"16a86895-1d82-4a57-b6cd-2db437c7a2b1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Read","command":"callback"},"parentToolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","toolUseID":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","timestamp":"2026-02-17T19:24:45.636Z","uuid":"f30ea963-5576-4052-a0fb-a7fb62b1991e"}
{"parentUuid":"8cfdd902-0876-440c-9934-18b386dc4511","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01W6HRD4Ni7g7sS4jeSW47B9","type":"tool_result","content":"     1‚Üí\\section{Surveillance et suivi}\n     2‚Üí\n     3‚Üí\\subsection{Suivi quotidien (auto-rapport patient)}\n     4‚Üí\n     5‚Üí\\begin{longtable}{p{3.5cm}p{4.5cm}p{5.5cm}}\n     6‚Üí\\toprule\n     7‚Üí\\textbf{Param√®tre} & \\textbf{Comment mesurer} & \\textbf{Cible} \\\\\n     8‚Üí\\midrule\n     9‚ÜíNiveau d'√©nergie & √âchelle 0-10, matin et soir & Stabilit√© tendance, √©viter <3/10 \\\\\n    10‚Üí\\midrule\n    11‚ÜíFonction cognitive & √âchelle 0-10 & Stabilit√© tendance \\\\\n    12‚Üí\\midrule\n    13‚ÜíAcouph√®nes & Pr√©sent/absent + intensit√© 0-10 & Utiliser comme biomarqueur fatigue \\\\\n    14‚Üí\\midrule\n    15‚ÜíDouleur & √âchelle 0-10 + localisation & Identifier corr√©lations activit√©-douleur \\\\\n    16‚Üí\\midrule\n    17‚ÜíFr√©quence cardiaque & Moniteur continu, enregistrer max & Rester sous 97 bpm \\\\\n    18‚Üí\\midrule\n    19‚ÜíSommeil & Heures, qualit√©, perturbations & Am√©liorer continuit√© \\\\\n    20‚Üí\\midrule\n    21‚ÜíTemps debout & Minutes cumul√©es & Rester dans enveloppe \\\\\n    22‚Üí\\midrule\n    23‚ÜíM√©dicaments pris & Doses exactes et timing & Assurer coh√©rence \\\\\n    24‚Üí\\bottomrule\n    25‚Üí\\end{longtable}\n    26‚Üí\n    27‚Üí\\subsection{√âvaluation hebdomadaire}\n    28‚Üí\n    29‚Üí\\begin{longtable}{p{6cm}p{7.5cm}}\n    30‚Üí\\toprule\n    31‚Üí\\textbf{Param√®tre} & \\textbf{Objectif} \\\\\n    32‚Üí\\midrule\n    33‚Üí√âpisodes PEM (compte, s√©v√©rit√©, d√©clencheurs) & Calibration seuil activit√© \\\\\n    34‚Üí\\midrule\n    35‚ÜíFr√©quence migraines & Efficacit√© traitement \\\\\n    36‚Üí\\midrule\n    37‚Üí√âv√©nements autonomes (faiblesse, tremblements, pouls √©lev√©) & Identification sch√©ma \\\\\n    38‚Üí\\midrule\n    39‚ÜíTendance capacit√© fonctionnelle globale & Trajectoire maladie \\\\\n    40‚Üí\\bottomrule\n    41‚Üí\\end{longtable}\n    42‚Üí\n    43‚Üí\\subsection{Si nouveaux m√©dicaments d√©marr√©s}\n    44‚Üí\n    45‚Üí\\begin{longtable}{p{3.5cm}p{5cm}p{4.5cm}}\n    46‚Üí\\toprule\n    47‚Üí\\textbf{M√©dicament} & \\textbf{Surveillance cl√©} & \\textbf{Fr√©quence} \\\\\n    48‚Üí\\midrule\n    49‚ÜíIvabradine & FC repos, sympt√¥mes bradycardie & Quotidien 2 semaines, puis hebdo \\\\\n    50‚Üí\\midrule\n    51‚ÜíPropranolol & FC, TA, niveau fatigue, tol√©rance exercice & Quotidien 2 semaines \\\\\n    52‚Üí\\midrule\n    53‚ÜíMidodrine & TA en d√©cubitus (avant s'allonger), picotements cuir chevelu & Chaque dose 1 semaine \\\\\n    54‚Üí\\midrule\n    55‚ÜíFludrocortisone & TA, poids, niveaux potassium & TA quotidien; analyses √† 2 et 6 semaines \\\\\n    56‚Üí\\midrule\n    57‚ÜíPyridostigmine & Sympt√¥mes GI, crampes musculaires, FC & Quotidien 1 semaine \\\\\n    58‚Üí\\bottomrule\n    59‚Üí\\end{longtable}\n    60‚Üí\n    61‚Üí\\subsection{Crit√®res de succ√®s pour essais m√©dicamenteux}\n    62‚Üí\n    63‚Üí\\begin{longtable}{p{4cm}p{9.5cm}}\n    64‚Üí\\toprule\n    65‚Üí\\textbf{Crit√®re} & \\textbf{D√©finition} \\\\\n    66‚Üí\\midrule\n    67‚Üí\\textbf{Succ√®s} & $\\geq$ 20\\% r√©duction √©v√©nements autonomes ET/OU $\\geq$ 2 points am√©lioration √©nergie quotidienne moyenne \\\\\n    68‚Üí\\midrule\n    69‚Üí\\textbf{Succ√®s partiel} & Am√©lioration sympt√¥mes sans gains √©nergie OU am√©lioration √©nergie avec nouveaux effets secondaires \\\\\n    70‚Üí\\midrule\n    71‚Üí\\textbf{√âchec} & Pas d'am√©lioration apr√®s dur√©e essai ad√©quate OU effets secondaires intol√©rables \\\\\n    72‚Üí\\midrule\n    73‚Üí\\textbf{Dur√©e essai} & Minimum 4 semaines pour chaque m√©dicament avant √©valuation (6-8 semaines pour LDN) \\\\\n    74‚Üí\\bottomrule\n    75‚Üí\\end{longtable}\n    76‚Üí\n    77‚Üí\\section{QUESTIONS POUR DISCUSSION}\n    78‚Üí\n    79‚Üí\\noindent\\textit{\\textbf{Note:} Dans le cadre de mon ME/CFS, je ne consulte actuellement que 2 m√©decins:}\n    80‚Üí\\begin{itemize}\n    81‚Üí\\item \\textit{G√©n√©raliste, pour petits trucs habituels}\n    82‚Üí\\item \\textit{Sp√©cialiste en m√©decine interne g√©n√©rale, pour ME/CFS}\n    83‚Üí\\end{itemize}\n    84‚Üí\n    85‚Üí\\noindent\\textit{Les questions ci-dessous sont organis√©es par domaine de sp√©cialit√© pour faciliter la discussion, mais c'est le sp√©cialiste en m√©decine interne g√©n√©rale qui g√®re tous ces aspects. √Ä priori, je ne souhaite pas consulter d'autres sp√©cialistes.}\n    86‚Üí\n    87‚Üí\\vspace{1em}\n    88‚Üí\n    89‚Üí\\subsection{Pour m√©decin g√©n√©raliste / soins primaires}\n    90‚Üí\n    91‚Üí\\begin{enumerate}\n    92‚Üí\\item Vu les √©v√©nements r√©currents de dysr√©gulation autonome (10-13 f√©v), une r√©f√©rence urgente en cardiologie ou m√©decine autonome est-elle justifi√©e?\n    93‚Üí\\item Le sch√©ma actuel d'utilisation intermittente de stimulant (Ritalin certains jours, pas d'autres) contribue-t-il aux √©v√©nements autonomes de rebond? Une utilisation quotidienne coh√©rente √† faible dose serait-elle plus s√ªre?\n    94‚Üí\\item Pouvons-nous obtenir mesure glucose sanguin pendant le prochain √©pisode pseudo-hypoglyc√©mique pour exclure vraie hypoglyc√©mie?\n    95‚Üí\\item Panel m√©tabolique de base et niveaux cortisol devraient-ils √™tre v√©rifi√©s vu l'instabilit√© autonome?\n    96‚Üí\\end{enumerate}\n    97‚Üí\n    98‚Üí\\subsection{Pour cardiologie / sp√©cialiste autonome}\n    99‚Üí\n   100‚Üí\\begin{enumerate}\n\n<system-reminder>\nWhenever you read a file, you should consider whether it would be considered malware. You CAN and SHOULD provide analysis of malware, what it is doing. But you MUST refuse to improve or augment the code. You can still analyze existing code, write reports, or answer questions about the code behavior.\n</system-reminder>\n"}]},"uuid":"a1777226-1281-4787-9d91-82214293a443","timestamp":"2026-02-17T19:24:45.635Z","sourceToolAssistantUUID":"8cfdd902-0876-440c-9934-18b386dc4511"}
{"parentUuid":"a1777226-1281-4787-9d91-82214293a443","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01MvHiMxNL9Ubi7bQQcB4ham","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01B3ofEfShdkpKwC3ysrMfqG","name":"Grep","input":{"pattern":"paradox|sensitiz|tolerance|tachyphylaxis|rebound|accumul","path":"/home/nicky/code/health-me-cfs/contents/part3-treatment","output_mode":"content","head_limit":30},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":8801,"cache_read_input_tokens":13113,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":8801},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtMNKJJrPZmQzwrG5M","type":"assistant","uuid":"9fa38c36-9d6a-45a6-a11d-235a84b46bcf","timestamp":"2026-02-17T19:24:47.394Z"}
{"parentUuid":"9fa38c36-9d6a-45a6-a11d-235a84b46bcf","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01B3ofEfShdkpKwC3ysrMfqG","toolUseID":"toolu_01B3ofEfShdkpKwC3ysrMfqG","timestamp":"2026-02-17T19:24:47.525Z","uuid":"6806fdc1-bef0-4e7a-b4fd-339eefb5c7ed"}
{"parentUuid":"6806fdc1-bef0-4e7a-b4fd-339eefb5c7ed","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_01B3ofEfShdkpKwC3ysrMfqG","toolUseID":"toolu_01B3ofEfShdkpKwC3ysrMfqG","timestamp":"2026-02-17T19:24:47.525Z","uuid":"f16fe1b7-509e-409c-92d4-6b506c397bdd"}
{"parentUuid":"9fa38c36-9d6a-45a6-a11d-235a84b46bcf","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01B3ofEfShdkpKwC3ysrMfqG","type":"tool_result","content":"contents/part3-treatment/ch17-lifestyle-interventions.tex:31:    \\item Worsening anaerobic threshold (earlier lactate accumulation)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:150:[Omitted long matching line]\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:210:A subset of ME/CFS patients (approximately 15\\% based on non-celiac wheat sensitivity biomarker studies~\\cite{Uhde2018}) reports that wheat consumption exacerbates exercise intolerance and PEM severity. The underlying mechanism likely involves a synergistic interaction between wheat-induced gut barrier dysfunction and exercise-induced intestinal ischemia.\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:212:\\begin{speculation}[Wheat-Primed Exercise Intolerance in ME/CFS]\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:254:\\textbf{Implication}: Many cases of patient-attributed wheat sensitivity are actually fructan sensitivity or mixed FODMAP intolerance. This complicates claims about gluten-specific mechanisms and requires careful dietary control in elimination protocols (see \\emph{Clinical Implementation} section below).\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:258:If wheat-primed exercise intolerance is valid:\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:263:    \\item Exercise tolerance (steps, activity duration before PEM) should improve measurably in responders during elimination (estimated 10--30\\% improvement)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:275:    \\item FODMAP intolerance highly prevalent in ME/CFS; distinguishing gluten vs.\\ FODMAP effects requires careful dietary control\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:283:For patients reporting wheat-exacerbated exercise intolerance, a structured 4--6 week elimination trial with proper FODMAP control and objective monitoring may identify responders:\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:291:Expected outcomes in responders: PEM reduction 20--50\\%, improved exercise tolerance, GI symptom resolution.\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:321:    \\item If GI symptoms return with high-FODMAP reintroduction, FODMAP intolerance confirmed (separate from gluten-specific effects)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:329:    \\item \\textbf{Bread}: Rice bread, certified gluten-free bread (avoid high-fiber versions if GI intolerance)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:364:    \\item Progressive tolerance of higher workloads\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:445:Despite exercise intolerance, complete immobility causes problems (muscle atrophy, joint stiffness, orthostatic intolerance worsening). The goal is \\textbf{movement within the energy envelope}---enough to prevent deconditioning complications without triggering PEM.\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:509:    \\item \\textbf{Sustained tolerance required}: Maintain new level for 2--4 weeks before further increase\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:57:    \\item \\textbf{Multi-system targeting}: Rather than treating ME/CFS as a single entity, protocols address documented dysfunction in mast cells (Section~\\ref{sec:allergies-mast-cells}), autonomic/cardiovascular function (Chapter~\\ref{ch:cardiovascular}), sleep architecture, pain sensitization, metabolic state, and immune activation simultaneously.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:59:    \\item \\textbf{Metabolic support framework}: The electrolyte/ORS protocols and mitochondrial interventions target the documented hypometabolic state and chronic lactate accumulation, treating ME/CFS metabolically similar to prolonged athletic overtraining.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:199:    \\item[Subtype B (Autonomic-Primary):] Orthostatic intolerance and dysautonomia dominate. Cognitive function relatively preserved.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:209:        \\item \\textbf{Priority 2}: Muscle-targeted rehabilitation (passive NMES, gentle movement within tolerance)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:241:    \\item \\textbf{Orthostatic intolerance} (can't stand without dizziness, need to lie down constantly)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:260:    \\item[$\\square$] Nausea, bloating, diarrhea, constipation, food intolerances ‚Üí \\textbf{Protocol 5 (GI)}\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:272:    \\item Orthostatic intolerance worsens cognitive function and triggers crashes\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:367:        \\item \\textbf{Critical}: All food must be fresh; histamine accumulates in aging food\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:517:\\subsubsection{Protocol 2: Orthostatic Intolerance Management}\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:522:Orthostatic intolerance severely limits function in most severe ME/CFS patients (Section~\\ref{sec:orthostatic-mechanisms}). Cerebral hypoperfusion (Section~\\ref{sec:cerebral-blood-flow}) contributes to cognitive dysfunction and fatigue. Reduced blood volume (Section~\\ref{sec:blood-volume}) and autonomic dysfunction (Section~\\ref{sec:ans-pathophysiology}) can be partially corrected with immediate interventions.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:526:\\textbf{Principle for severe cases}: Prescription medications (fludrocortisone, midodrine) provide FASTER and MORE COMPLETE relief than salt/fluids alone for severe orthostatic intolerance. If you can get same-day prescription, START prescription + non-pharmacologic measures together for maximum effect. If prescription requires waiting, start non-pharmacologic measures immediately while pursuing prescription.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:573:            \\item \\textbf{Effect}: Relief may begin within 15--30 minutes (improved orthostatic tolerance, reduced dizziness, better cognition)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:582:        \\item \\textbf{Justification for high-dose sodium in ME/CFS with orthostatic intolerance}:\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:584:            \\item \\textbf{Blood volume deficiency}: ME/CFS patients with POTS/orthostatic intolerance have demonstrated reductions in plasma volume (8--14\\% below normal). High sodium intake with adequate fluids expands blood volume, improving standing blood pressure and cerebral perfusion.\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:585:            \\item \\textbf{Mechanism}: Sodium retention by kidneys increases extracellular fluid volume. In healthy individuals, excess sodium raises blood pressure harmfully. In POTS/orthostatic intolerance, baseline blood volume is low; sodium loading normalizes volume without causing harmful hypertension in most patients.\n\n[Showing results with pagination = limit: 30, offset: 0]"}]},"uuid":"3aefd462-6480-470f-a1a6-2d4e7b839da9","timestamp":"2026-02-17T19:24:47.525Z","sourceToolAssistantUUID":"9fa38c36-9d6a-45a6-a11d-235a84b46bcf"}
{"parentUuid":"3aefd462-6480-470f-a1a6-2d4e7b839da9","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01S6nLN66UEa2DL42FXXDwX3","type":"message","role":"assistant","content":[{"type":"text","text":"Now let me search for existing content on drug interactions, CYP450, chronopharmacology, and related pharmacology topics already in the project."}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":7206,"cache_read_input_tokens":21914,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":7206},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtuKS4ALrjTt5FRE9M","type":"assistant","uuid":"32842348-4ceb-48e9-b279-355a6b0e00d6","timestamp":"2026-02-17T19:24:51.674Z"}
{"parentUuid":"32842348-4ceb-48e9-b279-355a6b0e00d6","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01S6nLN66UEa2DL42FXXDwX3","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01FpWkiR5xbah4bW2N4JeBZW","name":"Grep","input":{"pattern":"CYP450|cytochrome|metabolizer|pharmacogenom|chronopharm|circadian.*drug|first.dose|nocebo","path":"/home/nicky/code/health-me-cfs/contents","output_mode":"content","head_limit":20,"-i":true},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":7206,"cache_read_input_tokens":21914,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":7206},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtuKS4ALrjTt5FRE9M","type":"assistant","uuid":"b1ef27f8-6cd2-4191-8cd9-c9c5f94dc5a1","timestamp":"2026-02-17T19:24:54.393Z"}
{"parentUuid":"b1ef27f8-6cd2-4191-8cd9-c9c5f94dc5a1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01FpWkiR5xbah4bW2N4JeBZW","toolUseID":"toolu_01FpWkiR5xbah4bW2N4JeBZW","timestamp":"2026-02-17T19:24:54.536Z","uuid":"58e91bd2-5147-4325-8638-13872cc4d2ff"}
{"parentUuid":"58e91bd2-5147-4325-8638-13872cc4d2ff","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_01FpWkiR5xbah4bW2N4JeBZW","toolUseID":"toolu_01FpWkiR5xbah4bW2N4JeBZW","timestamp":"2026-02-17T19:24:54.536Z","uuid":"1830577f-7cc6-47f8-983b-6c4bc4121846"}
{"parentUuid":"b1ef27f8-6cd2-4191-8cd9-c9c5f94dc5a1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01FpWkiR5xbah4bW2N4JeBZW","type":"tool_result","content":"contents/part4-research/ch25-translational-findings.tex:898:    \\item \\textbf{Complex IV impairment}: Particularly affects cytochrome c oxidase (Complex IV)\ncontents/part4-research/ch25a-research-infrastructure.tex:476:    \\item Pharmacogenomics (drug metabolism variants: CYP2D6, CYP2C19)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:277:    \\item Placebo and nocebo effects are significant in dietary interventions and cannot be controlled without double-blind protocols (e.g., wheat hidden in capsules), limiting confidence in patient-reported outcomes (PEM severity, GI symptoms)\ncontents/part3-treatment/ch17-lifestyle-interventions.tex:343:    \\item Nocebo effect: Expectation of benefit may bias subjective symptom reporting. Objective tracking (steps, PEM severity scale) essential.\ncontents/part1-clinical/ch04-sections/ch04-07-novel-framework.tex:483:    \\item \\textbf{Drug interaction monitoring}: Cimetidine is a CYP450 inhibitor affecting metabolism of many medications (warfarin, phenytoin, theophylline, benzodiazepines, beta-blockers, calcium channel blockers)\ncontents/part1-clinical/ch05-subgroups.tex:495:This phenotype is based on clinical case series and mechanistic reasoning, not randomized controlled trials. Cimetidine has documented drug interactions (CYP450 inhibitor) and requires physician supervision. See Appendix~H for detailed evidence assessment and safety considerations. Do not attempt self-treatment based on this phenotype description.\ncontents/part3-treatment/ch15-medications-systems.tex:1165:Cimetidine is a CYP450 inhibitor (particularly CYP1A2, CYP2D6, CYP3A4). It may increase levels of medications metabolized by these enzymes, including:\ncontents/part3-treatment/ch15-medications-systems.tex:1271:CYP450 inhibition & Strong (1A2, 2D6, 3A4) & Minimal \\\\\ncontents/part3-treatment/ch15-medications-systems.tex:1278:\\textbf{Clinical implication}: Famotidine cannot be substituted for cimetidine when immunomodulation is the therapeutic goal. However, for pure acid suppression in patients requiring CYP450-metabolized medications, famotidine is preferred.\ncontents/part3-treatment/ch15-medications-systems.tex:1482:    \\item \\textbf{Metabolic differences}: Variant CYP450 activity (ultra-rapid or poor metabolizers)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:302:            \\item \\textbf{First dose can be started ANY TIME today} (once prescription obtained)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:315:            \\item \\textbf{First dose can be taken ANY TIME today} (15-20 minutes before next meal)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:327:            \\item \\textbf{First dose can be taken TONIGHT}\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:344:            \\item \\textbf{First dose can be taken ANY TIME today}\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:358:            \\item \\textbf{First dose can be taken ANY TIME today} (before next meal)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:658:            \\item \\textbf{First dose can be taken ANY TIME today} (avoid evening dosing first day)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:673:            \\item \\textbf{First dose can be taken ANY TIME today} (morning preferred once prescription obtained)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:687:            \\item \\textbf{First dose can be taken ANY TIME today} (with food)\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:746:            \\item \\textbf{First dose}: Can start TONIGHT at appropriate time\ncontents/part3-treatment/ch14a-urgent-action-severe.tex:752:            \\item \\textbf{First dose}: Tonight, 1 hour before bed\n\n[Showing results with pagination = limit: 20, offset: 0]"}]},"uuid":"7c514ab9-b27c-4979-a3a9-83a4a6add953","timestamp":"2026-02-17T19:24:54.536Z","sourceToolAssistantUUID":"b1ef27f8-6cd2-4191-8cd9-c9c5f94dc5a1"}
{"parentUuid":"7c514ab9-b27c-4979-a3a9-83a4a6add953","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01S6nLN66UEa2DL42FXXDwX3","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_015ZNPHFsxyVcR9m6JozjTHk","name":"Grep","input":{"pattern":"sensitiz|central sensitiz|small fiber|mast cell.*drug|histamine.*medication","path":"/home/nicky/code/health-me-cfs/contents","output_mode":"content","head_limit":20,"-i":true},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":7206,"cache_read_input_tokens":21914,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":7206},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBtuKS4ALrjTt5FRE9M","type":"assistant","uuid":"7eeea484-6032-42ad-8f3e-0be0f88be458","timestamp":"2026-02-17T19:24:55.889Z"}
{"parentUuid":"7eeea484-6032-42ad-8f3e-0be0f88be458","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_015ZNPHFsxyVcR9m6JozjTHk","toolUseID":"toolu_015ZNPHFsxyVcR9m6JozjTHk","timestamp":"2026-02-17T19:24:56.050Z","uuid":"eefd380e-65a3-4cef-9a51-64c158b7d71f"}
{"parentUuid":"eefd380e-65a3-4cef-9a51-64c158b7d71f","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:Grep","command":"callback"},"parentToolUseID":"toolu_015ZNPHFsxyVcR9m6JozjTHk","toolUseID":"toolu_015ZNPHFsxyVcR9m6JozjTHk","timestamp":"2026-02-17T19:24:56.050Z","uuid":"64ec1bc8-de78-465a-aee2-4da097812b19"}
{"parentUuid":"7eeea484-6032-42ad-8f3e-0be0f88be458","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_015ZNPHFsxyVcR9m6JozjTHk","type":"tool_result","content":"contents/part1-clinical/ch03-additional-symptoms.tex:38:Photophobia likely reflects both central sensitization (amplification of sensory signals in the brain) and mitochondrial dysfunction in retinal cells, which have exceptionally high energy demands. Visual processing itself is energetically expensive, consuming significant ATP.\ncontents/part1-clinical/ch03-additional-symptoms.tex:76:Touch sensitivity reflects small fiber neuropathy and central sensitization. Peripheral nerve dysfunction causes abnormal tactile processing, while central amplification interprets benign touch as noxious stimuli.\ncontents/part1-clinical/ch03-additional-symptoms.tex:192:Paresthesias reflect small fiber neuropathy, documented in many ME/CFS patients via skin biopsy. Small nerve fibers are metabolically demanding and vulnerable to energy deficit and oxidative stress.\ncontents/part1-clinical/ch03-additional-symptoms.tex:355:Myalgia reflects lactic acid accumulation from anaerobic metabolism, muscle hypoxia, central sensitization amplifying pain signals, and possible muscle microtrauma from energy-deficient muscle fibers.\ncontents/part1-clinical/ch03-additional-symptoms.tex:371:Joint pain without visible pathology likely reflects central sensitization, periarticular tissue energy deficit, microcirculatory dysfunction, and in some cases, low-grade inflammatory or autoimmune processes.\ncontents/part3-treatment/ch14c-pediatric-severe.tex:420:\\subsection{Sensitization Prevention Protocol}\ncontents/part3-treatment/ch14c-pediatric-severe.tex:421:\\label{subsec:ped-severe-sensitization}\ncontents/part3-treatment/ch14c-pediatric-severe.tex:423:Severe pediatric ME/CFS patients are vulnerable to progressive sensitization---the phenomenon where increasing numbers of triggers (infections, environmental exposures, activities) progressively reduce symptom tolerance. Early intervention to prevent sensitization can preserve quality of life and potentially prevent further deterioration.\ncontents/part3-treatment/ch14c-pediatric-severe.tex:425:\\begin{protocol}[Pediatric Sensitization-Prevention Protocol]\ncontents/part3-treatment/ch14c-pediatric-severe.tex:426:\\label{protocol:ped-sensitization-prevention}\ncontents/part3-treatment/ch14c-pediatric-severe.tex:430:A multi-component approach targets neuroinflammatory activation, which underlies both PEM and progressive sensitization. The goal is to interrupt the cycle where each crash and each infection creates lasting sensitization (see Chapter~\\ref{ch:neurological} for discussion of \\hyperref[hyp:pem-kindling-sensitization]{PEM kindling hypothesis} and Chapter~\\ref{ch:immune-dysfunction} for discussion of \\hyperref[hyp:infection-damage-ratchet]{infection damage ratchet mechanisms}).\ncontents/part3-treatment/ch14c-pediatric-severe.tex:456:    \\item \\textbf{Mechanism}: Endocannabinoid system modulation; reduces neuroinflammation and neuropathic sensitization\ncontents/part3-treatment/ch14c-pediatric-severe.tex:484:Preventing overexertion is critical to preventing sensitization cascade:\ncontents/part3-treatment/ch14c-pediatric-severe.tex:494:\\textbf{Infection Prevention as Sensitization Prevention}\ncontents/part3-treatment/ch14c-pediatric-severe.tex:496:Each infection causes both acute PEM and lasting sensitization increases. Aggressive prevention is sensitization prevention:\ncontents/part3-treatment/ch14c-pediatric-severe.tex:513:    \\item \\textbf{Each prevented crash}: Each crash not occurring is a sensitization cascade prevented\ncontents/part3-treatment/ch14c-pediatric-severe.tex:519:[Omitted long matching line]\ncontents/part3-treatment/ch18-emerging-therapies.tex:561:    \\item \\textbf{NMDA receptor antagonism}: Reduces central sensitization and neuronal hyperexcitability---potentially relevant to ME/CFS-associated pain amplification and sensory hypersensitivity\ncontents/part3-treatment/ch18-emerging-therapies.tex:592:    \\item \\textbf{Mechanistic rationale}: Strong theoretical basis given NMDA involvement in central sensitization, neuroinflammation in ME/CFS pathophysiology, and ATP depletion rendering neurons vulnerable to glutamate excitotoxicity\ncontents/part3-treatment/ch18-emerging-therapies.tex:632:    \\item May be most appropriate for patients with prominent pain, central sensitization features, or treatment-refractory fatigue who have exhausted safer options\n\n[Showing results with pagination = limit: 20, offset: 0]"}]},"uuid":"558d0aa6-e178-401a-b89a-129fc2de4d24","timestamp":"2026-02-17T19:24:56.050Z","sourceToolAssistantUUID":"7eeea484-6032-42ad-8f3e-0be0f88be458"}
{"parentUuid":"558d0aa6-e178-401a-b89a-129fc2de4d24","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_018sqE3sK9ZqUVES7poo1txi","type":"message","role":"assistant","content":[{"type":"text","text":"Now let me do targeted web searches on key pharmacological phenomena in ME/CFS to enrich the brainstorming."}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2615,"cache_read_input_tokens":29120,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2615},"output_tokens":4,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBuXtrtqeZXNPa2wAeY","type":"assistant","uuid":"22b5ccba-7c1d-41de-b1aa-df7b9dbd0c0c","timestamp":"2026-02-17T19:24:59.595Z"}
{"parentUuid":"22b5ccba-7c1d-41de-b1aa-df7b9dbd0c0c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_018sqE3sK9ZqUVES7poo1txi","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01GG6M3B9cq4NFuTF8tq3qWf","name":"WebSearch","input":{"query":"ME/CFS paradoxical drug responses medication sensitivity pharmacology 2024 2025"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2615,"cache_read_input_tokens":29120,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2615},"output_tokens":4,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBuXtrtqeZXNPa2wAeY","type":"assistant","uuid":"ef64248c-66fb-48e5-a6fb-14be12dd0fc9","timestamp":"2026-02-17T19:25:00.323Z"}
{"parentUuid":"ef64248c-66fb-48e5-a6fb-14be12dd0fc9","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_018sqE3sK9ZqUVES7poo1txi","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01Qdm9o49qkdcR4DvrDzRgta","name":"WebSearch","input":{"query":"low dose naltrexone dose response curve optimal dosing ME/CFS 2024 2025"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2615,"cache_read_input_tokens":29120,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2615},"output_tokens":4,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBuXtrtqeZXNPa2wAeY","type":"assistant","uuid":"5ad9b528-4cad-4406-b673-1e953e1801b6","timestamp":"2026-02-17T19:25:01.104Z"}
{"parentUuid":"5ad9b528-4cad-4406-b673-1e953e1801b6","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_018sqE3sK9ZqUVES7poo1txi","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01LfX2Sndviepo6svitC6P4s","name":"WebSearch","input":{"query":"SSRI activation syndrome energy before mood suicide risk timeline pharmacology"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":2615,"cache_read_input_tokens":29120,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":2615},"output_tokens":4,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBuXtrtqeZXNPa2wAeY","type":"assistant","uuid":"6ded8a5a-ad0c-46e8-b14a-03788c897a7a","timestamp":"2026-02-17T19:25:01.865Z"}
{"parentUuid":"6ded8a5a-ad0c-46e8-b14a-03788c897a7a","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01GG6M3B9cq4NFuTF8tq3qWf","toolUseID":"toolu_01GG6M3B9cq4NFuTF8tq3qWf","timestamp":"2026-02-17T19:25:08.808Z","uuid":"ce97d114-5143-456a-9537-52bed30f9aae"}
{"parentUuid":"ef64248c-66fb-48e5-a6fb-14be12dd0fc9","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01GG6M3B9cq4NFuTF8tq3qWf","type":"tool_result","content":"Web search results for query: \"ME/CFS paradoxical drug responses medication sensitivity pharmacology 2024 2025\"\n\nLinks: [{\"title\":\"1 Report of the ME/CFS Research Roadmap Working Group of Council May 15, 2024\",\"url\":\"https://www.ninds.nih.gov/sites/default/files/2024-05/Report%20of%20the%20MECFS%20Research%20Roadmap%20Working%20Group%20of%20Council_508C.pdf\"},{\"title\":\"Frontiers | Medication use and symptomology in North American women with myalgic encephalomyelitis/chronic fatigue syndrome\",\"url\":\"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1543158/full\"},{\"title\":\"Including: How new drugs are assessed and brought into use Treating ME/CFS\",\"url\":\"https://meassociation.org.uk/wp-content/uploads/2025/02/Treating-ME-CFS-APRIL-2024.pdf\"},{\"title\":\"Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map - NCBI Bookshelf\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK613143/\"},{\"title\":\"Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Mayo Clinic Proceedings\",\"url\":\"https://www.mayoclinicproceedings.org/article/s0025-6196(23)00402-0/fulltext\"},{\"title\":\"Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6787585/\"},{\"title\":\"Patient-reported treatment outcomes in ME/CFS and long COVID | PNAS\",\"url\":\"https://www.pnas.org/doi/10.1073/pnas.2426874122\"},{\"title\":\"312 Medication Responses in Chronic Fatigue Syndrome (CFS) and Non-CFS Subjects - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3512701/\"},{\"title\":\"Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives\",\"url\":\"https://www.mdpi.com/2077-0383/13/2/325\"},{\"title\":\"What Is A Paradoxical Effect? -\",\"url\":\"https://www.hotelcaliforniabythesea.com/2024/09/12/what-is-a-paradoxical-effect/\"}]\n\nI've performed the web search on ME/CFS paradoxical drug responses and medication sensitivity. Here are the key findings from recent research (2024-2025):\n\n## Medication Sensitivity in ME/CFS\n\nMany patients with ME/CFS use supplements because of medication sensitivity or lack of pharmacologic options offered by medical professionals. There is a clinical perception that Chronic Fatigue Syndrome (CFS) subjects have greater drug sensitivity and \"allergy\" than the rest of the population.\n\n## Current Medication Use Patterns\n\nA 2025 study from Frontiers in Medicine found that analgesic medications (31.7%) were the most frequently used, followed by psychotropic (26.4%), and immune-related medications (10.6%). The study also noted that a U-shaped relationship between ME/CFS-related symptom medication use and functional capacity as assessed by self-reported physical movement (hours/week) was evident.\n\n## Treatment Challenges and Heterogeneous Responses\n\nRecent studies analyzing patient-reported outcomes from over 3,900 individuals identified symptom-based patient subgroups with distinct responses to therapies. Additionally, current treatment guidelines focus on symptom management, but with no clear target or causative mechanism, remission rates are low, and fewer than 5% of patients return to their pre-morbid activity levels.\n\n## Limited Pharmacological Research\n\nWhile 164 studies focused on treatment and management of ME/CFS, only 24 investigated pharmacological interventions. This highlights a significant gap in understanding medication responses in this population.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"932c72ef-a8b2-4ceb-a71f-c4d876748732","timestamp":"2026-02-17T19:25:08.808Z","sourceToolAssistantUUID":"ef64248c-66fb-48e5-a6fb-14be12dd0fc9"}
{"parentUuid":"932c72ef-a8b2-4ceb-a71f-c4d876748732","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01Qdm9o49qkdcR4DvrDzRgta","toolUseID":"toolu_01Qdm9o49qkdcR4DvrDzRgta","timestamp":"2026-02-17T19:25:08.837Z","uuid":"044bc37d-1b27-4e73-a169-5fa546c1750c"}
{"parentUuid":"5ad9b528-4cad-4406-b673-1e953e1801b6","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01Qdm9o49qkdcR4DvrDzRgta","type":"tool_result","content":"Web search results for query: \"low dose naltrexone dose response curve optimal dosing ME/CFS 2024 2025\"\n\nLinks: [{\"title\":\"Low Dose Naltrexone\",\"url\":\"https://batemanhornecenter.org/wp-content/uploads/2024/09/Low-Dose-Naltrexone-LDN-20240911.pdf\"},{\"title\":\"Low-Dose Naltrexone For ME/CFS: Dose-Finding\",\"url\":\"https://clinicaltrials.gov/study/NCT07285473\"},{\"title\":\"Full article: Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/21641846.2019.1692770\"},{\"title\":\"Real World Effectiveness and Tolerability of Low Dose Naltrexone to Tr | JPR\",\"url\":\"https://www.dovepress.com/real-world-effectiveness-and-tolerability-of-low-dose-naltrexone-to-tr-peer-reviewed-fulltext-article-JPR\"},{\"title\":\"Low-dose Naltrexone for Post-COVID Fatigue Syndrome\",\"url\":\"https://clinicaltrials.gov/study/NCT05430152\"},{\"title\":\"LDN 2024 DOSINGINFORMATION FOR PRESCRIBERS LDN 2024 Dosing Information\",\"url\":\"https://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf\"},{\"title\":\"Effect of low dose naltrexone for long covid: a systematic review | medRxiv\",\"url\":\"https://www.medrxiv.org/content/10.1101/2025.09.09.25335451v1.full\"},{\"title\":\"Low dose naltrexone - MEpedia\",\"url\":\"https://me-pedia.org/wiki/Low_dose_naltrexone\"},{\"title\":\"Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician‚Äôs Practice - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12702260/\"},{\"title\":\"LDN 2024 PRESCRIBER GUIDE LDN 2024 Prescriber Guide\",\"url\":\"https://ldnresearchtrust.org/sites/default/files/2024-02/Prescriber-Guide-2024.pdf\"}]\n\nBased on the web search results, here's what I found regarding low-dose naltrexone (LDN) dosing for ME/CFS:\n\n## Dosing Range and Recommendations\n\nWhen naltrexone is dosed between 0.5 mg and 6 mg it is termed low dose naltrexone or LDN. Clinical practice data shows effectiveness at doses of 3.0‚Äì4.5 mg/day for ME/CFS.\n\n## Titration Guidelines\n\nFor ME/CFS, a recommended approach is to start slow and build up slowly: 0.5-1mg daily for 14 days increasing by 0.5 to 1mg every 2 weeks until at 4.5mg or highest tolerated dose. Alternatively, a conservative approach would be to start at 0.5 mg daily and increase by 0.5 mg every 5 days, though in more sensitive patients, a slower titration may be preferred, while other patients may tolerate a quicker titration.\n\n## Mechanism and Effectiveness\n\nAt these doses, there is reduction in glial inflammatory response and upregulation of endogenous opioid signaling by transient opioid receptor blockage, with the blockade lasting for about 4 hours after LDN is dosed.\n\nA positive treatment response to LDN was reported by 73.9% of patients, with most experiencing improved vigilance/alertness and improved physical and cognitive performance.\n\n## Recent Clinical Trial Activity\n\nAn Australian team is assessing LDN for both ME/CFS and long covid. However, the search results don't contain detailed dose-response curve data specific to ME/CFS from 2024-2025 studies yet.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"87c15bfc-a15c-48b6-a198-ea16696f0784","timestamp":"2026-02-17T19:25:08.837Z","sourceToolAssistantUUID":"5ad9b528-4cad-4406-b673-1e953e1801b6"}
{"parentUuid":"87c15bfc-a15c-48b6-a198-ea16696f0784","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01LfX2Sndviepo6svitC6P4s","toolUseID":"toolu_01LfX2Sndviepo6svitC6P4s","timestamp":"2026-02-17T19:25:12.375Z","uuid":"66c0a059-be36-4e27-b298-f561e69325b3"}
{"parentUuid":"6ded8a5a-ad0c-46e8-b14a-03788c897a7a","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01LfX2Sndviepo6svitC6P4s","type":"tool_result","content":"Web search results for query: \"SSRI activation syndrome energy before mood suicide risk timeline pharmacology\"\n\nLinks: [{\"title\":\"Antidepressant‚ÄêInduced Suicidality: An Update - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6493906/\"},{\"title\":\"Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study | Neuropsychopharmacology\",\"url\":\"https://www.nature.com/articles/s41386-021-01179-z\"},{\"title\":\"Expanding the Black Box ‚Äî Depression, Antidepressants, and the Risk of Suicide | New England Journal of Medicine\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMp078015\"},{\"title\":\"Suicide and Antidepressants: What Current Evidence Indicates - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3353604/\"},{\"title\":\"Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2867356/\"},{\"title\":\"Why Do Antidepressants Cause Suicidal Thoughts? | Charlie Health\",\"url\":\"https://www.charliehealth.com/post/why-do-antidepressants-cause-suicidal-thoughts\"},{\"title\":\"An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide - A Nationwide Register-Based Case-Crossover Study - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3767591/\"},{\"title\":\"Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8970236/\"},{\"title\":\"Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project | International Journal of Neuropsychopharmacology | Oxford Academic\",\"url\":\"https://academic.oup.com/ijnp/article/21/9/814/5043110\"},{\"title\":\"Antidepressants and Suicide Risk: A Comprehensive Overview - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4034101/\"}]\n\nHere are the search results for your query about SSRI activation syndrome, energy, mood, suicide risk, timeline, and pharmacology:\n\n## Key Findings:\n\n**Activation Syndrome Overview:**\nAn activation syndrome with agitation, insomnia, and irritability may occur during the course of SSRI treatment. Symptoms of behavioral activation by antidepressants can vary greatly, manifesting as any combination of the following: irritability, agitation, somatic symptoms of anxiety, panic attacks, restlessness, hostility, aggressiveness, insomnia, disinhibition, emotional labiality, impulsivity, social withdrawal, restlessness, hypomania/mania, paranoia or other psychotic symptoms, or other unusual changes in behavior or mood.\n\n**Energy Before Mood Improvement:**\nClinicians have known for years that during the first few weeks of treatment with antidepressants, some patients become \"activated\" ‚Äîenergized and agitated ‚Äî before their depressed mood lifts, and that combination makes them more likely to act on preexisting suicidal impulses. One explanation for this might be that certain depressed patients (particularly those with psychomotor retardation) might already be harboring suicidal thoughts, but lack of will to act on these impulses until their energy is increased during the early phase of antidepressant treatment before mood has improved.\n\n**Timeline:**\nIt is generally believed that the risk of suicidality associated with treatment emerges early on, perhaps during the first 2 weeks of therapy. More specifically, the suicidal adverse effects occurred within the first week (in 71% of the cases) or the first 2 weeks (93%) after onset or dosage increase of the antidepressant. The suicide peak in day 8 to 11 and in day 12-15 argue both in favor of the activation syndrome theory and of the biological mechanism through alteration in serotonin levels.\n\n**Pharmacological Mechanism:**\nFrom a biological perspective, antidepressants increase neurotransmitter activity in the brain, particularly serotonin. The initial boost in serotonin may cause mood instability in some individuals before therapeutic effects take hold, possibly contributing to suicidal thoughts.\n\n**Clinical Considerations:**\nClose monitoring and follow-up care should be provided for patients after initiation of a new antidepressant.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"3684e4de-4c7e-4361-9b0e-0b477e1016c1","timestamp":"2026-02-17T19:25:12.375Z","sourceToolAssistantUUID":"6ded8a5a-ad0c-46e8-b14a-03788c897a7a"}
{"parentUuid":"3684e4de-4c7e-4361-9b0e-0b477e1016c1","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_011a3eSzSKxJeNEUtcMAbn3d","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01Xcr4aeLWwbfgyh5FqvTgNJ","name":"WebSearch","input":{"query":"drug tachyphylaxis tolerance chronic fatigue POTS dysautonomia medication 2024"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":3531,"cache_read_input_tokens":31735,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":3531},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBvjqjNJiPxoRxYoxXz","type":"assistant","uuid":"23893625-6d22-40d3-af03-bd91ce0c9875","timestamp":"2026-02-17T19:25:16.514Z"}
{"parentUuid":"23893625-6d22-40d3-af03-bd91ce0c9875","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_011a3eSzSKxJeNEUtcMAbn3d","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01Poqru7ijiVGpo7jTBRAtP6","name":"WebSearch","input":{"query":"mast cell activation syndrome medication trigger histamine release drug sensitivity MCAS"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":3531,"cache_read_input_tokens":31735,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":3531},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBvjqjNJiPxoRxYoxXz","type":"assistant","uuid":"caab0c85-3789-44ac-9871-e02ddfda4845","timestamp":"2026-02-17T19:25:17.500Z"}
{"parentUuid":"caab0c85-3789-44ac-9871-e02ddfda4845","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_011a3eSzSKxJeNEUtcMAbn3d","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_0147gfQzb44reSwKiFxqWuZb","name":"WebSearch","input":{"query":"pediatric ME/CFS medication pharmacokinetics age-dependent drug response adolescent"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1,"cache_creation_input_tokens":3531,"cache_read_input_tokens":31735,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":3531},"output_tokens":25,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBvjqjNJiPxoRxYoxXz","type":"assistant","uuid":"9970bda0-f78a-4284-913d-ad00defd92b0","timestamp":"2026-02-17T19:25:17.889Z"}
{"parentUuid":"9970bda0-f78a-4284-913d-ad00defd92b0","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01Poqru7ijiVGpo7jTBRAtP6","toolUseID":"toolu_01Poqru7ijiVGpo7jTBRAtP6","timestamp":"2026-02-17T19:25:26.608Z","uuid":"a17ea978-8634-4361-9d66-6faf805ecfbf"}
{"parentUuid":"caab0c85-3789-44ac-9871-e02ddfda4845","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01Poqru7ijiVGpo7jTBRAtP6","type":"tool_result","content":"Web search results for query: \"mast cell activation syndrome medication trigger histamine release drug sensitivity MCAS\"\n\nLinks: [{\"title\":\"Mast Cell Activation Syndrome (MCAS): Symptoms & Treatment\",\"url\":\"https://my.clevelandclinic.org/health/diseases/mast-cell-activation-syndrome\"},{\"title\":\"Mast Cell Activation Syndrome (MCAS)\",\"url\":\"https://www.aaaai.org/conditions-treatments/related-conditions/mcas\"},{\"title\":\"Mast cell activation syndrome - Wikipedia\",\"url\":\"https://en.wikipedia.org/wiki/Mast_cell_activation_syndrome\"},{\"title\":\"Medications to Avoid with MCAS\",\"url\":\"https://www.histamined.com/post/medications-to-avoid-with-mcas\"},{\"title\":\"Mast Cell Activation Syndrome - PoTS UK\",\"url\":\"https://www.potsuk.org/about-pots/associated-conditions/mcas/\"},{\"title\":\"What is Mast Cell Activation Syndrome (MCAS)? - Allergy & Asthma Network\",\"url\":\"https://allergyasthmanetwork.org/mast-cell-diseases/mcas/\"},{\"title\":\"Mast Cell Activation Syndrome: Symptoms, Causes, and Treatment\",\"url\":\"https://www.webmd.com/allergies/what-is-mast-cell-activation-syndrome\"},{\"title\":\"Mast cell activation syndrome: An up-to-date review of literature - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11212760/\"},{\"title\":\"Pharmacological treatment options for mast cell activation disease - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4903110/\"},{\"title\":\"Management | Mast Cell Action\",\"url\":\"https://www.mastcellaction.org/management\"}]\n\nI've successfully completed the web search for your query. Here's a summary of the key findings about mast cell activation syndrome (MCAS), medication triggers, and histamine release:\n\n## Key Information Found:\n\n**What is MCAS:**\nMCAS is an immunological condition in which mast cells, a type of white blood cell, inappropriately and excessively release chemical mediators, such as histamine, resulting in a range of chronic symptoms, sometimes including anaphylaxis or near-anaphylaxis attacks.\n\n**Medication Triggers:**\nCertain medications are among one of the main triggers of MCAS. Medications may increase the symptoms of MCAS by increasing mast cell activation, triggering histamine release, increasing histamine intolerance, or inhibiting the function of the DAO enzyme, which breaks down histamine.\n\n**Drug Sensitivity:**\nSometimes, people also react to the ingredients in the medications, meaning it can take some time to find the proper treatment.\n\n**Treatment Approaches:**\nMedication is often divided into H1 antihistamines such as cetirizine, fexofenadine, loratadine and H2 antihistamines such as cimetidine and famotidine. These medications help dampen down the effect of histamine released by the mast cells.\n\nMedication that stabilises the mast cells to stop them releasing their chemicals includes sodium chromoglycate, ketotifen and montelukast.\n\nThe search results provide comprehensive information about MCAS pathophysiology, diagnostic criteria, and management strategies including medication management and trigger avoidance.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"392f33c3-154f-49e7-8514-c2829e27895d","timestamp":"2026-02-17T19:25:26.608Z","sourceToolAssistantUUID":"caab0c85-3789-44ac-9871-e02ddfda4845"}
{"parentUuid":"392f33c3-154f-49e7-8514-c2829e27895d","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_0147gfQzb44reSwKiFxqWuZb","toolUseID":"toolu_0147gfQzb44reSwKiFxqWuZb","timestamp":"2026-02-17T19:25:26.775Z","uuid":"e0063e2a-9036-48f4-8471-4e7d48961bb0"}
{"parentUuid":"9970bda0-f78a-4284-913d-ad00defd92b0","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_0147gfQzb44reSwKiFxqWuZb","type":"tool_result","content":"Web search results for query: \"pediatric ME/CFS medication pharmacokinetics age-dependent drug response adolescent\"\n\nLinks: [{\"title\":\"Pharmacokinetics and Pharmacodynamics in Children versus Adults - Rational Therapeutics for Infants and Children - NCBI Bookshelf\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK225507/\"},{\"title\":\"Developmental Pharmacokinetics in Pediatric Populations - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4341411/\"},{\"title\":\"Paediatric pharmacokinetics: key considerations - PMC - NIH\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4345950/\"},{\"title\":\"Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3857037/\"},{\"title\":\"Pharmacokinetics in Children - Pediatrics - Merck Manual Professional Edition\",\"url\":\"https://www.merckmanuals.com/professional/pediatrics/principles-of-drug-treatment-in-children/pharmacokinetics-in-children\"},{\"title\":\"Considerations for Pediatric ME/CFS | ME/CFS | CDC\",\"url\":\"https://www.cdc.gov/me-cfs/hcp/clinical-care/pediatric-me-cfs.html\"},{\"title\":\"c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children ‚Äì A c4c expert group white paper - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9788092/\"},{\"title\":\"Pharmacokinetic changes with growth and development between birth and adulthood - O'Hara - 2017 - Journal of Pharmacy Practice and Research - Wiley Online Library\",\"url\":\"https://onlinelibrary.wiley.com/doi/full/10.1002/jppr.1373\"},{\"title\":\"Pediatric Pharmacology - PsychDB\",\"url\":\"https://www.psychdb.com/meds/pharmacology/pediatric\"},{\"title\":\"Physiological Changes and Pediatric Pharmacokinetics - Genomind\",\"url\":\"https://genomind.com/providers/physiological-changes-and-pediatric-pharmacokinetics/\"}]\n\nI've completed the web search for your query on pediatric ME/CFS medication pharmacokinetics, age-dependent drug response, and adolescent considerations. Here's a summary of the key findings:\n\n## General Pediatric Pharmacokinetics and Age-Dependent Drug Response\n\nPharmacokinetic parameters including half-life, apparent volume of distribution, and total plasma clearance vary among different age groups even when normalized by body weight, with age being an important determinant of pharmacokinetic parameters in the pediatric population. Age dependency is a function of body composition, organ functions, ontogeny of drug biotransformation pathways, disease progression, and pharmacological receptor functions.\n\n## Adolescent-Specific Considerations\n\nStudies suggest a higher level of CYP3A4 activity in children with gradual maturation to adult levels during adolescence, with even more complexity revealed in adolescent metabolism and differences in drug metabolism between the sexes. Differences exist between pediatric age groups for pharmacokinetics and pharmacodynamics in both efficacy and safety.\n\n## Key Pharmacokinetic Processes Affected\n\nDevelopmental changes in the pediatric setting occur across the pharmacokinetic processes of absorption, distribution, metabolism and excretion with each reaching adult equivalents at different ages.\n\n## Pediatric ME/CFS Symptom Management\n\nAdolescents and younger children with ME/CFS have a wide range of symptoms that can be difficult to manage, with a goal of managing ME/CFS in adolescent and younger children being to reduce symptoms that limit daily activity.\n\nThe search results provide comprehensive information on general pediatric pharmacokinetics but limited specific data on ME/CFS-specific medications and their age-dependent responses in adolescents.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"f45200ce-8aee-4fcb-ac20-3ef217828e6f","timestamp":"2026-02-17T19:25:26.775Z","sourceToolAssistantUUID":"9970bda0-f78a-4284-913d-ad00defd92b0"}
{"parentUuid":"f45200ce-8aee-4fcb-ac20-3ef217828e6f","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01Xcr4aeLWwbfgyh5FqvTgNJ","toolUseID":"toolu_01Xcr4aeLWwbfgyh5FqvTgNJ","timestamp":"2026-02-17T19:25:27.482Z","uuid":"d1d7edc5-3fe7-4176-838b-81d9c9725a31"}
{"parentUuid":"23893625-6d22-40d3-af03-bd91ce0c9875","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01Xcr4aeLWwbfgyh5FqvTgNJ","type":"tool_result","content":"Web search results for query: \"drug tachyphylaxis tolerance chronic fatigue POTS dysautonomia medication 2024\"\n\nLinks: [{\"title\":\"Frontiers | Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic\",\"url\":\"https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1515486/full\"},{\"title\":\"Medication Management - Dysautonomia Support Network\",\"url\":\"https://www.dysautonomiasupport.org/medication-management/\"},{\"title\":\"Effective Dysautonomia Treatments: Managing Dysautonomia | re-origin\",\"url\":\"https://www.re-origin.com/articles/dysautonomia-treatments\"},{\"title\":\"Top 20 Dysautonomia Pharmacological Treatments - The Dysautonomia Project\",\"url\":\"https://thedysautonomiaproject.org/top-20-dysautonomia-pharmacological-treatments/\"},{\"title\":\"Non-Pharmacological and Pharmacological Management of Cardiac Dysautonomia Syndromes - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7533143/\"},{\"title\":\"Adderall and POTS: Do Amphetamines treat POTS? | The EDS Clinic\",\"url\":\"https://www.eds.clinic/articles/amphetamines-for-pots-treatment\"},{\"title\":\"Pharmacological Treatments for POTS/Dysautonomia: What You Need to Know | A Group Medical Practice & Rehabilitation and Pain Management Physician Specialist located in Dover, Newark and Lewes, DE | Delaware NeuroRehab\",\"url\":\"https://www.deneurorehab.com/post/pharmacological-treatments-for-potsdysautonomia-what-you-need-to-know\"},{\"title\":\"Principles of Autonomic Medicine Version 1.0 -- 562 -- MANAGING DYSAUTONOMIAS\",\"url\":\"https://www.dysautonomiainternational.org/pdf/PAM_7_Managing.pdf\"},{\"title\":\"Current Treatments in Familial Dysautonomia - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4236240/\"},{\"title\":\"Dysautonomia: Causes, Symptoms and Treatments - The Dysautonomia Project\",\"url\":\"https://thedysautonomiaproject.org/dysautonomia/\"}]\n\nI've completed the web search for your query on drug tachyphylaxis, tolerance, chronic fatigue, POTS, dysautonomia, and medication information from 2024. Here are the key findings:\n\n## Overview of POTS and Dysautonomia\n\nPOTS is a complex form of dysautonomia that presents with abnormal autonomic reflexes upon standing, leading to symptoms such as lightheadedness, tachycardia, fatigue, and cognitive impairment. Chronic features of POTS include fatigue, deconditioning, comorbid psychiatric concerns, medical expenditures, and reduced physical, occupational and social functioning.\n\n## Common Medication Treatments\n\nAmong the most common medications for POTS symptoms are beta-blockers, fludrocortisone, and midodrine. Additionally, stimulants such as Adderall (dextroamphetamine), Vyvanse (lisdexamfetamine), and Modafinil are sometimes used to treat dysautonomia, including POTS.\n\n## Important Note on Drug Tolerance\n\nThe search results revealed one specific mention of tachyphylaxis (rapid development of drug tolerance): Histamine H2 receptor antagonists (ranitidine/cimetidine/nizatidine) can be used acutely to reduce gastric acidity, but tachyphylaxis soon occurs. This appears in the context of familial dysautonomia treatment for gastroesophageal reflux.\n\n## 2024 Research Update\n\nA systematic review of the literature was performed to identify studies of oral medications for the management of POTS, searching for published manuscripts through 6 April 2024.\n\nThe search results focused primarily on specific medication options and management strategies for dysautonomia rather than extensively discussing general drug tolerance and tachyphylaxis issues in this population.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"3748a248-250b-4f13-9600-fab3f2783a01","timestamp":"2026-02-17T19:25:27.482Z","sourceToolAssistantUUID":"23893625-6d22-40d3-af03-bd91ce0c9875"}
{"parentUuid":"3748a248-250b-4f13-9600-fab3f2783a01","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01B68tygbxhsBqcC4wGjFDSE","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_011AqVEp6c455JXV9MujcFzy","name":"WebSearch","input":{"query":"medication rebound effect versus withdrawal distinction pharmacology clinical significance"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1868,"cache_creation_input_tokens":1244,"cache_read_input_tokens":35266,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":1244},"output_tokens":19,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBwrHTE6CJFsazF3PDZ","type":"assistant","uuid":"27cd4ca6-a5ba-41e2-a4e5-f3c8b84bb432","timestamp":"2026-02-17T19:25:31.674Z"}
{"parentUuid":"27cd4ca6-a5ba-41e2-a4e5-f3c8b84bb432","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01B68tygbxhsBqcC4wGjFDSE","type":"message","role":"assistant","content":[{"type":"tool_use","id":"toolu_01VNNsLHW7S9XdpKicdinEHv","name":"WebSearch","input":{"query":"chronopharmacology time of day drug administration cortisol melatonin antihistamine effectiveness circadian"},"caller":{"type":"direct"}}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1868,"cache_creation_input_tokens":1244,"cache_read_input_tokens":35266,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":1244},"output_tokens":19,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBwrHTE6CJFsazF3PDZ","type":"assistant","uuid":"039a4762-e4d5-46a4-a4db-afaaadc0a63d","timestamp":"2026-02-17T19:25:32.488Z"}
{"parentUuid":"039a4762-e4d5-46a4-a4db-afaaadc0a63d","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_01VNNsLHW7S9XdpKicdinEHv","toolUseID":"toolu_01VNNsLHW7S9XdpKicdinEHv","timestamp":"2026-02-17T19:25:40.361Z","uuid":"bdd84aed-7a18-449f-85d8-1e476e7343af"}
{"parentUuid":"039a4762-e4d5-46a4-a4db-afaaadc0a63d","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_01VNNsLHW7S9XdpKicdinEHv","type":"tool_result","content":"Web search results for query: \"chronopharmacology time of day drug administration cortisol melatonin antihistamine effectiveness circadian\"\n\nLinks: [{\"title\":\"Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11586979/\"},{\"title\":\"Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy\",\"url\":\"https://www.mdpi.com/2624-5175/6/4/43\"},{\"title\":\"Circadian Variation in Efficacy of Medications - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8268638/\"},{\"title\":\"Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy - PubMed\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39584972/\"},{\"title\":\"Circadian Effects of Drug Responses - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8525652/\"},{\"title\":\"Importance of Circadian Rhythm in Drug Administration Timing\",\"url\":\"https://www.chronobiologyinmedicine.org/journal/view.php?number=133\"},{\"title\":\"Circadian Variation in Efficacy of Medications - Walton - 2021 - Clinical Pharmacology & Therapeutics - Wiley Online Library\",\"url\":\"https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2073\"},{\"title\":\"Circadian Variation in Efficacy of Medications - PubMed\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/33025623/\"},{\"title\":\"Chronobiotic - an overview | ScienceDirect Topics\",\"url\":\"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/chronobiotic\"},{\"title\":\"Timing matters for medications ‚Äì your circadian rhythm influences how well treatments work and how much they might harm you\",\"url\":\"https://theconversation.com/timing-matters-for-medications-your-circadian-rhythm-influences-how-well-treatments-work-and-how-much-they-might-harm-you-194906\"}]\n\nI've completed the web search for your query about chronopharmacology. Here's a summary of what I found:\n\n## Key Findings on Chronopharmacology\n\n**Impact of Timing on Drug Effectiveness:**\nThe timing of drug administration can significantly affect a medication's effectiveness and side effects, with the impact varying by up to ten times based on circadian rhythms.\n\n**Circadian Influence on Drug Metabolism:**\nThe absorption, biodistribution, effects on target organs, half-life, metabolism, and elimination of drugs are all influenced by the body's circadian rhythms.\n\n**Cortisol and Melatonin Patterns:**\nCortisol increases from low levels during the night period to peak during the early morning hours, while levels of melatonin, growth hormone, and TSH peak during the middle of the night. Melatonin is dosed at night, as close as possible to its circadian peak, in the treatment of sleep disorders.\n\n**Clinical Applications:**\nBy closely monitoring circadian variations in cortisol, melatonin, and key clock genes, as well as by deepening our understanding of the metabolisms and pharmacokinetics of antipsychotic medications, a chronotherapy approach for psychiatric patients could significantly enhance patient care.\n\n**Current Gaps in Practice:**\nGold-standard double-blind clinical studies should be conducted to determine the best time of day for optimal effectiveness of medications, and time of day should be tracked and reported as an important biological variable in ongoing clinical studies, similar to sex.\n\nThe research emphasizes that timing of medication administration is a critical but often overlooked factor in optimizing treatment outcomes.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"6e714948-d9b8-443b-94f0-ed614aefce6c","timestamp":"2026-02-17T19:25:40.361Z","sourceToolAssistantUUID":"039a4762-e4d5-46a4-a4db-afaaadc0a63d"}
{"parentUuid":"6e714948-d9b8-443b-94f0-ed614aefce6c","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"progress","data":{"type":"hook_progress","hookEvent":"PostToolUse","hookName":"PostToolUse:WebSearch","command":"./.claude/hooks/context-cost-monitor.sh"},"parentToolUseID":"toolu_011AqVEp6c455JXV9MujcFzy","toolUseID":"toolu_011AqVEp6c455JXV9MujcFzy","timestamp":"2026-02-17T19:25:43.741Z","uuid":"73c9bfaa-8d08-413b-ae26-3a2604774ae0"}
{"parentUuid":"27cd4ca6-a5ba-41e2-a4e5-f3c8b84bb432","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","type":"user","message":{"role":"user","content":[{"tool_use_id":"toolu_011AqVEp6c455JXV9MujcFzy","type":"tool_result","content":"Web search results for query: \"medication rebound effect versus withdrawal distinction pharmacology clinical significance\"\n\nLinks: [{\"title\":\"Rebound effect - Wikipedia\",\"url\":\"https://en.wikipedia.org/wiki/Rebound_effect\"},{\"title\":\"Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders - PubMed\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39710834/\"},{\"title\":\"Rebound effect of modern drugs: serious adverse event unknown by health professionals - PubMed\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/24211013/\"},{\"title\":\"Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders | Pharmacological Reports\",\"url\":\"https://link.springer.com/article/10.1007/s43440-024-00689-z\"},{\"title\":\"Rebound Effect - an overview | ScienceDirect Topics\",\"url\":\"https://www.sciencedirect.com/topics/neuroscience/rebound-effect\"},{\"title\":\"Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development - PMC\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7425303/\"},{\"title\":\"The Role of Rebound Effect in Addiction | UK Rehab\",\"url\":\"https://www.uk-rehab.com/addiction/psychology/rebound-effect/\"},{\"title\":\"Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development | Brain Communications | Oxford Academic\",\"url\":\"https://academic.oup.com/braincomms/article/1/1/fcz025/5588408\"},{\"title\":\"The rebound effect and its association with psychotropic drugs - GSD - a group of clinics in Italy\",\"url\":\"https://www.gsdinternational.com/news/the-rebound-effect-and-its-association-with-psychotropic-drugs\"},{\"title\":\"What Is a Drug Rebound Effect?\",\"url\":\"https://californiadetox.com/rebound-effect/\"}]\n\nBased on the search results, here's a comprehensive overview of the distinction between medication rebound effects and withdrawal, and their clinical significance:\n\n## Key Definitions\n\nThe rebound effect is the emergence or re-emergence of symptoms that were either absent or controlled while taking a medication, but appear when that same medication is discontinued or reduced in dosage. In contrast, a withdrawal syndrome is the appearance of a new cluster of symptoms (not present before treatment) that are unpleasant and generally last a few days to a few weeks rather than 1 or 2 days.\n\n## Clinical Characteristics: Three Distinct Phenomena\n\nRecent pharmacological literature distinguishes between three related but separate phenomena:\n\n1. **Rebound Effect**: The rebound effect is clinically characterized by the relapse of the disease symptoms that are controlled by medication, but of greater severity than those before treatment.\n\n2. **Withdrawal Syndrome**: Withdrawal syndrome, based on physical dependence, results in life-threatening, long-lasting manifestations such as seizures and delirium, different from the treated disease. Originally withdrawal syndrome was described for drugs with addictive properties such as barbiturates or benzodiazepines.\n\n3. **Discontinuation Syndrome**: Sudden abrupt of antidepressants or antipsychotics may cause discontinuation symptoms including movement or sensory disturbances, sleep disturbances, and hyperarousal but generally of less severity comparing to withdrawal syndrome.\n\n## Shared Features and Pathophysiology\n\nThe common feature of these phenomena is a quick onset, usually limited duration depending on the drug's half-life and remission after restarting the therapy. The aforementioned syndromes are physiologically based on the predominance of cellular counter-regulations as an effect of the sudden abrupt of a regularly taken medication.\n\n## Severity Distinctions\n\nDiscontinuation syndrome is not considered as serious and usually spontaneously resolving. In contrast, withdrawal syndromes can be far more severe. A practical example illustrates this: Rebound insomnia is the brief (1 or 2 nights) exacerbation of the original symptom. It does not reflect the presence of a withdrawal syndrome, which would involve the appearance of new symptoms lasting for more than a night or two.\n\n## Clinical Significance\n\nUnderstanding these distinctions is crucial for patient care. The rebound effect represents a common side effect to numerous classes of modern drugs, may cause serious and fatal disorders in patients. Knowledge of their pathogenesis and symptoms resulting from drug discontinuation may be helpful in syndrome management and expectantly reduces the risk of diagnostic and therapeutic errors.\n\n\nREMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks."}]},"uuid":"bc050a8f-f80a-44ed-8e5e-843b2c7e0719","timestamp":"2026-02-17T19:25:43.740Z","sourceToolAssistantUUID":"27cd4ca6-a5ba-41e2-a4e5-f3c8b84bb432"}
{"parentUuid":"bc050a8f-f80a-44ed-8e5e-843b2c7e0719","isSidechain":true,"userType":"external","cwd":"/home/nicky/code/health-me-cfs","sessionId":"c49f7cae-7830-4595-8ff2-3707bdd9b17a","version":"2.1.42","gitBranch":"main","agentId":"ad180fa","slug":"scalable-dazzling-nygaard","message":{"model":"claude-opus-4-6","id":"msg_01TqFHwx9VFDqNmVBptdAh7U","type":"message","role":"assistant","content":[{"type":"text","text":"Now I have sufficient context from both the project and current literature. Here is the comprehensive R2 brainstorming output.\n\n---\n\n# Phase 6 R2 Creative Brainstorming: Medication Effect Patterns in ME/CFS\n\n---\n\n## A. Additional Effect Patterns (Beyond the 6 Planned)\n\n### 1. Paradoxical Responses\n\n**Description:** Medications producing the opposite of their expected pharmacological effect. In ME/CFS, this is not rare but systematically under-documented.\n\n**Examples already in the project:** Modafinil at 400mg producing worse outcomes than placebo (documented in the patient's medical report at `/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/06-gestion-medicale.tex`, line 95: \"400mg a montr√© des effets PIRES que placebo\"). Stimulants causing sedation in some ME/CFS patients. First-generation antihistamines paradoxically causing agitation rather than sedation.\n\n**Rationale for inclusion:** Paradoxical responses are distinct from dose-dependent curves (Type 5) because the response is qualitatively inverted, not merely quantitatively suboptimal. In ME/CFS, these may be mechanistically informative -- a paradoxical response to a stimulant might indicate that the targeted neurotransmitter system is already overcompensating, and the drug tips it past a tipping point. MCAS comorbidity further complicates this: drugs can trigger mast cell degranulation, producing effects unrelated to their pharmacological target.\n\n**Sub-patterns:**\n- Stimulant-induced sedation or \"shutdown\" (possible catecholamine depletion in already-depleted systems)\n- Anxiolytic-induced paradoxical agitation (benzodiazepine paradox, more common in CNS inflammation)\n- Analgesic-induced hyperalgesia (opioid-induced hyperalgesia, relevant to central sensitization)\n- Antihistamine-induced histamine release (some formulations contain excipients that trigger mast cells)\n\n### 2. Drug-Induced PEM (Medication as Metabolic Trigger)\n\n**Description:** Certain medications or medication-related activities can directly trigger post-exertional malaise, not through side effects per se, but by imposing metabolic demands or autonomic stress that exceed the patient's energy envelope.\n\n**Rationale for inclusion:** This is specific to ME/CFS and not captured by any of the 6 planned types. It represents a unique interaction between the disease's core pathology (energy metabolism dysfunction) and pharmacological intervention.\n\n**Sub-patterns:**\n- Sympathomimetic drugs (stimulants, decongestants) enabling activity beyond metabolic capacity -- the \"energy borrowing\" problem already documented for the patient's Ritalin use (line 65 of `06-gestion-medicale.tex`)\n- Immune-activating treatments (vaccines, immunotherapy) triggering PEM through immune activation energy cost\n- Drugs requiring hepatic metabolism imposing energy demands on an already energy-compromised liver\n- Physical act of medication administration in severe patients (swallowing, sitting up) as PEM trigger\n\n### 3. Tachyphylaxis and Tolerance Development\n\n**Description:** Progressive loss of drug effectiveness with continued use, requiring dose escalation to maintain the same effect. Distinct from withdrawal (Type 6) because it occurs during ongoing treatment, not upon discontinuation.\n\n**Rationale for inclusion:** Multiple ME/CFS-relevant medications develop tolerance: H2 receptor antagonists (tachyphylaxis documented in dysautonomia literature), sleep medications (benzodiazepines, Z-drugs), decongestants (rebound congestion), and potentially even LDN (though this is debated). This pattern is especially dangerous because patients may escalate doses without medical guidance.\n\n**Sub-patterns:**\n- Rapid tachyphylaxis (H2 blockers, decongestants -- days to weeks)\n- Slow tolerance (sleep medications, anxiolytics -- weeks to months)\n- Paradoxical sensitization (some patients become more sensitive rather than tolerant, possibly related to impaired drug metabolism)\n- Rotating medication strategies to prevent tolerance\n\n### 4. Excipient and Formulation Sensitivity\n\n**Description:** Adverse reactions not to the active pharmaceutical ingredient but to fillers, binders, coatings, dyes, preservatives, or delivery vehicle. In ME/CFS patients with MCAS, this is a substantial clinical problem.\n\n**Rationale for inclusion:** MCAS comorbidity (present in the patient case) means that excipients containing histamine liberators, dyes (especially tartrazine), preservatives (parabens, sulfites), or even lactose/gluten can trigger mast cell activation independent of the drug's pharmacological action. This leads to false attribution of drug intolerance when the problem is formulation-specific. Switching to a compounded version or different manufacturer sometimes resolves the \"intolerance.\"\n\n**Sub-patterns:**\n- Dye-triggered mast cell activation (tartrazine, FD&C colors)\n- Filler-related GI reactions (lactose, sorbitol, mannitol in patients with FODMAP sensitivity)\n- Extended-release coating reactions\n- Generic vs. brand bioequivalence issues (different excipient profiles)\n- Compounding as a solution for excipient-sensitive patients\n\n### 5. Chronopharmacological Variation (Time-of-Day Effects)\n\n**Description:** The same drug at the same dose can produce markedly different effects depending on when it is administered, driven by circadian variation in drug metabolism enzymes, receptor sensitivity, and physiological targets.\n\n**Rationale for inclusion:** ME/CFS patients often have disrupted circadian rhythms (documented extensively in the project's sleep sections). This creates a double problem: standard chronopharmacological advice may not apply because the patient's circadian clock is shifted, AND the disrupted rhythm itself changes drug metabolism. Drug timing can affect effectiveness by up to 10-fold according to chronopharmacology research.\n\n**Sub-patterns:**\n- Cortisol-dependent drug timing (corticosteroids should mimic natural cortisol curve; ME/CFS patients may have flattened curves)\n- Melatonin micro-dosing (0.3-0.5mg at physiological timing vs. pharmacological 3-5mg doses)\n- LDN timing (evening dosing to align with endorphin rebound during sleep)\n- Antihistamine sedation curve (cetrizine less sedating than first-generation, but timing still matters for MCAS patients with nocturnal histamine release peaks)\n- Stimulant timing relative to cortisol awakening response\n\n### 6. Cumulative Polypharmacy Interactions\n\n**Description:** Not a single drug-drug interaction but the emergent, unpredictable effects of multiple medications acting simultaneously on overlapping systems. Most drug interaction databases check pairs; ME/CFS patients often take 5-15 agents simultaneously.\n\n**Rationale for inclusion:** The patient case demonstrates this well -- LDN + cetirizine + methylphenidate + modafinil + supplements (CoQ10, B12, magnesium, lipoic acid) + melatonin represents at least 8 concurrent agents. The interaction space grows combinatorially. Some combinations produce synergistic benefits (LDN + antihistamines for neuroinflammation); others produce emergent harms not predictable from individual drug profiles.\n\n**Sub-patterns:**\n- Serotonin accumulation risk (multiple mild serotonergic agents summing to significant effect)\n- CYP450 competition (multiple drugs competing for same metabolic pathway, changing each other's effective dose)\n- Additive QTc prolongation risk\n- Supplement-drug interactions (St. John's Wort, grapefruit, quercetin as CYP inhibitors)\n- The \"deprescribing challenge\" -- removing one agent may unmask effects previously balanced by another\n\n### 7. Rebound Effects (Distinct from Withdrawal)\n\n**Description:** Re-emergence of the original symptoms in exaggerated form after drug discontinuation, distinct from withdrawal (new symptoms not present before treatment) and discontinuation syndrome (milder, self-limiting). Already documented for the patient's Ritalin use (lines 67-74 of `06-gestion-medicale.tex`).\n\n**Rationale for inclusion:** While the planned Type 6 covers \"withdrawal effects,\" the distinction between rebound, withdrawal, and discontinuation syndrome is clinically critical and often confused. Rebound is especially common with: antihistamines (rebound histamine release), proton pump inhibitors (rebound acid hypersecretion), decongestants (rhinitis medicamentosa), and stimulants (rebound fatigue/crash). The Ritalin rebound pattern in the patient case is a textbook example.\n\n**Sub-patterns:**\n- Same-day rebound (stimulant crash as medication wears off)\n- Next-day rebound (antihistamine withdrawal causing symptom flare)\n- Delayed rebound (PPI acid rebound appearing 2-3 days after discontinuation)\n- Rebound as diagnostic signal (severity of rebound may indicate degree of receptor adaptation)\n\n---\n\n## B. Per-Type Analysis\n\n---\n\n### Type 1: Transient Adverse Effects\n\n#### Sub-Patterns\n\n1. **Early activation syndrome** -- Agitation, insomnia, anxiety in first 1-2 weeks of SSRIs/SNRIs. Distinguished from the therapeutic effect by timeline (appears before benefit) and by quality (feels like \"wired but tired\" rather than improved energy). In ME/CFS patients with baseline autonomic instability, this activation can mimic or trigger PEM.\n\n2. **Immune reconstitution symptoms** -- When immunomodulators (LDN, low-dose immunoglobulin) begin restoring immune function, previously suppressed immune responses reactivate. Patients may experience flu-like symptoms, lymph node tenderness, and fatigue worsening that actually signals immune normalization rather than drug intolerance.\n\n3. **Gastrointestinal adaptation phase** -- Many drugs cause GI disturbance initially (nausea, diarrhea, constipation) that resolves as the enteric nervous system adapts. In ME/CFS patients with pre-existing gut dysfunction, this phase is amplified and prolonged, leading to premature drug discontinuation.\n\n4. **Histamine-mediated first-dose reaction** -- Some medications trigger mast cell degranulation on first exposure, producing a transient \"allergic\" response (flushing, tachycardia, headache) that does not recur with subsequent doses as mast cells desensitize. This is especially relevant in MCAS patients and is often misinterpreted as true drug allergy.\n\n5. **Sleep architecture disruption** -- LDN-induced vivid dreams/insomnia, melatonin-induced morning grogginess, or antihistamine-induced next-day sedation. These typically resolve within 1-3 weeks as neurotransmitter receptor populations adjust, but ME/CFS patients with fragile sleep may be especially affected.\n\n#### Treatment Implications\n\n1. **Pre-treatment counseling protocol**: Before starting any new medication, provide written timeline of expected transient effects with specific \"when to worry\" criteria. This reduces nocebo-driven discontinuation.\n\n2. **Graduated introduction alongside symptom diary**: Start new medications during a low-activity period so that transient effects are not confounded with PEM from concurrent activity.\n\n3. **Decision tree for continuing vs. stopping**: Develop explicit criteria -- if symptom X does not improve by week Y, discontinue. If symptom X is worsening rather than stable, discontinue immediately. If symptom X is stable and tolerable, continue with reassessment at week Z.\n\n4. **Dose-splitting for GI tolerance**: Many transient GI effects can be managed by splitting the daily dose initially (e.g., half dose twice daily rather than full dose once daily) and consolidating once tolerability is established.\n\n5. **MCAS pre-treatment**: For patients with known MCAS, consider pre-medicating with antihistamines before introducing new drugs, reducing histamine-mediated first-dose reactions.\n\n#### Research Questions\n\n1. Do ME/CFS patients have a longer transient adverse effect phase than the general population, and if so, does this correlate with any biomarker (inflammatory markers, autonomic function tests)?\n\n2. Can the severity of transient adverse effects predict eventual therapeutic response? (i.e., patients who experience immune reconstitution symptoms on LDN -- do they have better long-term outcomes than those with no initial effects?)\n\n3. What is the rate of premature drug discontinuation in ME/CFS compared to other chronic illness populations, and how much is attributable to transient effects vs. persistent intolerance?\n\n4. Does MCAS status predict first-dose histamine reactions, and does antihistamine pre-treatment reliably prevent them?\n\n---\n\n### Type 2: Therapeutic Lag\n\n#### Sub-Patterns\n\n1. **Neuroplasticity-dependent lag** -- Drugs acting through neuroplastic mechanisms (amitriptyline for pain, LDN for neuroinflammation) require weeks to months because they depend on receptor density changes, synaptic remodeling, or gene expression shifts. The lag is biological, not pharmacokinetic.\n\n2. **Tissue saturation lag** -- Some compounds (B12 for neurological recovery, CoQ10 for mitochondrial function, vitamin D for immune modulation) must accumulate to therapeutic tissue concentrations over weeks to months. Blood levels may normalize long before clinical benefit appears because the tissue compartment is still refilling.\n\n3. **Microbiome-mediated lag** -- Drugs affecting the gut-brain axis (probiotics, antimicrobials, even some supplements) may show benefits only after gut microbiome composition shifts, which takes 4-12 weeks. This is relevant given the documented gut-brain interactions in ME/CFS.\n\n4. **Stepwise benefit emergence** -- Rather than gradual continuous improvement, some patients experience sudden step-changes in function (e.g., \"nothing for 6 weeks, then suddenly better\"). This may reflect threshold effects where accumulated neurochemical changes cross a functional tipping point.\n\n5. **Lag-within-lag** -- Different symptoms respond at different rates to the same drug. For example, LDN may improve sleep within 2-4 weeks but take 3-6 months for pain, and 6-12 months for overall energy. Patients who judge effectiveness by only one symptom domain may prematurely declare failure.\n\n#### Treatment Implications\n\n1. **Medication-specific timeline contracts**: Before starting a drug, establish explicit agreement: \"We will evaluate this drug after X weeks/months. Unless you experience [specific stop criteria], please continue until the evaluation date.\"\n\n2. **Interim outcome markers**: Identify early signals that the drug is biologically active even before clinical benefit appears. For LDN: vivid dreams (indicates opioid receptor interaction). For B12: improved nail growth. For antihistamines: reduced skin reactivity.\n\n3. **Protected trial periods**: During the lag phase, avoid introducing other new treatments that could confound the evaluation. One new drug at a time during evaluation windows.\n\n4. **Domain-specific tracking**: Track multiple symptom domains independently so that early improvement in one domain is recognized even if the primary complaint has not yet responded.\n\n#### Research Questions\n\n1. What is the precise therapeutic lag for LDN in ME/CFS? The project mentions 6-8 weeks for trial evaluation (line 73 of `10-surveillance-interactions.tex`), but clinical experience suggests some patients require 3-6 months. Is there data on optimal trial duration?\n\n2. Does the lag period differ by ME/CFS subtype? Specifically, do patients with immune-predominant presentations show faster LDN response than those with metabolic-predominant presentations?\n\n3. Can pharmacogenomic profiling (CYP2D6, CYP2C19 status) predict lag duration for specific drugs?\n\n4. Is there a relationship between disease duration and therapeutic lag? Do longer-ill patients require longer trial periods because more tissue repair is needed?\n\n---\n\n### Type 3: Herxheimer Reactions\n\n#### Sub-Patterns\n\n1. **Classic Jarisch-Herxheimer** -- Worsening upon antimicrobial treatment (originally described in syphilis treatment). In ME/CFS, potentially relevant when treating chronic infections (EBV reactivation, small intestinal bacterial overgrowth). Mechanism: rapid pathogen die-off releases endotoxins/cellular debris, triggering inflammatory cascade.\n\n2. **Immune reconstitution inflammatory syndrome (IRIS)-like reactions** -- When immunomodulatory treatment restores immune surveillance, the immune system \"discovers\" previously tolerated infections or inflammatory foci and mounts an acute response. This is distinct from classic Herxheimer because it is not dependent on pathogen killing.\n\n3. **Detoxification reactions** -- Claimed in integrative medicine when treatments mobilize stored toxins (heavy metals, fat-soluble compounds) faster than elimination pathways can clear them. Evidence base is weak, but the subjective experience of patients is real and needs to be addressed even if the mechanism is debated.\n\n4. **Mast cell destabilization Herxheimer-mimics** -- In MCAS patients, new medications can trigger mast cell activation that mimics Herxheimer (fever, malaise, body aches, headache). This is mechanistically distinct (mast cell degranulation vs. pathogen die-off) but clinically indistinguishable without careful testing.\n\n#### Treatment Implications\n\n1. **Herxheimer vs. adverse reaction decision algorithm**: Develop explicit criteria to distinguish true Herxheimer (time-limited, follows initiation of antimicrobial, symptom profile matches inflammation) from adverse drug reaction (progressive worsening, new organ-specific symptoms, lab value changes). This distinction is critical because the management is opposite: Herxheimer means continue (possibly reduce dose temporarily), while adverse reaction means stop.\n\n2. **Supportive management during Herxheimer**: Increased hydration, electrolyte support, antihistamines for inflammatory symptoms, reduced activity to prevent PEM from the added inflammatory metabolic load.\n\n3. **Dose reduction strategy**: \"Pulsing\" antimicrobials (taking every other day or reducing dose) to reduce Herxheimer severity while maintaining therapeutic benefit.\n\n4. **Biomarker monitoring**: CRP, tryptase, or cytokine panels during suspected Herxheimer to characterize the inflammatory profile and distinguish from other causes.\n\n#### Research Questions\n\n1. Is there evidence for true Jarisch-Herxheimer reactions in ME/CFS antimicrobial treatment, or are the reported \"die-off\" reactions better explained by MCAS activation, nocebo effect, or simple drug intolerance?\n\n2. Can IRIS-like reactions occur in ME/CFS patients starting LDN or other immunomodulators, and if so, does the severity predict long-term immune function improvement?\n\n3. What percentage of reported \"Herxheimer reactions\" in ME/CFS integrative medicine are actually mast cell activation episodes?\n\n---\n\n### Type 4: Energy-Before-Mood Paradox\n\n#### Sub-Patterns\n\n1. **Classical antidepressant activation** -- SSRIs/SNRIs restore psychomotor energy within days to 2 weeks, while mood improvement requires 4-8 weeks. The intervening period (peak risk: days 8-15 per literature) leaves patients with enough energy to act on pre-existing suicidal ideation but insufficient mood improvement to reduce that ideation. Literature shows 71% of suicidal adverse events occur within the first week, 93% within the first 2 weeks.\n\n2. **Stimulant-enabled overactivity** -- In ME/CFS specifically, stimulants (methylphenidate, modafinil) restore subjective energy and cognitive function without restoring actual metabolic capacity. The patient \"feels\" capable of activity that exceeds their energy envelope, leading to PEM. This is the patient's documented Ritalin pattern: cognitive 8/10 on medication day, followed by energy 2/10 with autonomic event the next day.\n\n3. **Pain relief-enabled overactivity** -- When pain medications effectively control ME/CFS pain, the protective signal that would normally limit activity is removed. Patients do more because they hurt less, but their metabolic capacity has not changed, leading to delayed PEM that appears \"unexplained.\"\n\n4. **Autonomic medication-masked decompensation** -- Fludrocortisone or midodrine improving orthostatic tolerance allows patients to stand and walk more, but the underlying metabolic dysfunction means the increased activity exceeds their actual capacity. The hemodynamic improvement masks the metabolic cost.\n\n5. **Cognitive restoration without executive function** -- Some treatments improve processing speed and memory before restoring executive function (judgment, planning, impulse control). This creates a period where patients can think clearly enough to plan but lack the judgment to plan safely.\n\n#### Treatment Implications\n\n1. **Suicide risk monitoring protocol**: For any activating medication (SSRIs, stimulants, corticosteroids), implement structured check-ins at days 3, 7, 14, and 21. Use validated screening tools (PHQ-9, Columbia Suicide Severity Rating Scale). Provide crisis resources proactively.\n\n2. **Activity restriction during activation phase**: When starting activating medications, explicitly instruct patients that increased energy does NOT mean increased metabolic capacity. Maintain pre-medication activity limits for at least 4 weeks even if they feel capable of more.\n\n3. **Caregiver vigilance protocol**: Caregivers should be educated about this paradox and instructed to observe for behavioral changes: sudden increased activity, impulsive decisions, social withdrawal, or expressions of hopelessness despite appearing \"better.\" These are high-risk signals.\n\n4. **Stimulant pacing integration**: For ME/CFS patients on stimulants, combine with heart rate monitoring (the patient already has a 97 bpm limit documented). The stimulant-enabled feeling does not change the metabolic limit; the heart rate monitor provides an objective boundary.\n\n5. **Gradual activity expansion protocol**: After the initial activation phase, allow very gradual (5-10% per week) activity expansion, with mandatory 48-hour observation periods after each increase to detect delayed PEM.\n\n#### Research Questions\n\n1. Is the energy-before-mood paradox more dangerous in ME/CFS than in primary depression, because ME/CFS patients have the additional burden of chronic illness, loss of function, and social isolation compounding any mood disorder?\n\n2. Does the stimulant-enabled overactivity pattern (documented in the patient case) constitute a form of the energy-before-mood paradox, even without formal mood disorder? The mechanism is analogous: restored subjective capacity without restored actual capacity.\n\n3. What is the optimal monitoring protocol specifically for ME/CFS patients starting SSRIs, given their baseline higher rate of suicidal ideation and their unique metabolic constraints?\n\n4. Can wearable physiological monitoring (heart rate variability, activity tracking) provide early warning of the activation-without-mood-improvement window?\n\n---\n\n### Type 5: Dose-Dependent Benefit Curves\n\n#### Sub-Patterns\n\n1. **Inverted U-shape (hormetic) response** -- Benefit increases with dose up to an optimum, then declines. LDN is the paradigmatic example: no effect below 0.5mg, optimal at 1.5-4.5mg (patient-dependent), loss of benefit or worsening above 5mg (at full naltrexone doses, immunomodulatory benefit is lost and opioid blockade becomes dominant). Melatonin follows a similar pattern: physiological doses (0.3-0.5mg) may be more effective for circadian resetting than pharmacological doses (3-10mg), which can cause next-day grogginess and paradoxical insomnia.\n\n2. **Threshold effect (step function)** -- No benefit at all until a minimum concentration is reached, then sudden onset of benefit. This may explain why some patients report \"nothing happened\" for weeks then \"suddenly it started working.\" Tissue concentrations must cross a threshold before the biological cascade initiates. Examples: B12 for methylation, CoQ10 for mitochondrial electron transport.\n\n3. **Biphasic dose response** -- Low doses produce one effect, higher doses produce a qualitatively different effect. This is distinct from inverted U because the curve has two separate peaks at different doses. Example: aspirin at low dose (antiplatelet), medium dose (analgesic), high dose (anti-inflammatory). In ME/CFS: naltrexone at ultralow dose (0.001-0.01mg, opioid potentiation), low dose (1-5mg, immunomodulation), full dose (50mg, addiction treatment).\n\n4. **Weight-adjusted sensitivity** -- ME/CFS patients may require lower doses per kilogram than the general population, not merely because they are underweight but because of altered drug metabolism, reduced clearance, or increased receptor sensitivity. The \"start low go slow\" principle reflects this, but the quantitative relationship between patient characteristics and optimal dose is poorly characterized.\n\n5. **Time-dependent dose optimization** -- The optimal dose may change over the course of treatment. Initial low dose for tolerability, gradual increase to therapeutic dose, then possible dose reduction once the therapeutic effect is established (especially for drugs that cause receptor changes). This is documented for LDN but may apply more broadly.\n\n#### Treatment Implications\n\n1. **Systematic dose-finding protocols**: Rather than standard titration schedules, develop individualized dose-finding protocols using symptom tracking. Start at the lowest available dose, increase by the smallest available increment at fixed intervals (e.g., weekly), and track multiple symptom domains to identify the minimum effective dose.\n\n2. **\"Less is more\" education**: Explicitly educate patients and clinicians that in ME/CFS pharmacology, dose escalation past the optimal point often causes worsening. This counteracts the common assumption that \"if a little helps, more will help more.\"\n\n3. **Dose-reduction trials**: For patients stable on a medication, periodically attempt small dose reductions to determine whether they are on more than the minimum effective dose. This reduces side effects and polypharmacy burden.\n\n4. **Liquid formulation access**: Many optimal ME/CFS doses fall between available tablet sizes. Compounded liquid formulations allow precise dose adjustment (e.g., LDN at 1.75mg rather than being forced to choose between 1.5mg and 2mg capsules).\n\n#### Research Questions\n\n1. What is the shape of the LDN dose-response curve in ME/CFS, specifically? A dose-finding clinical trial (the Australian NCT07285473 trial is actively investigating this) could characterize this formally.\n\n2. Does melatonin follow an inverted-U dose-response for sleep quality in ME/CFS specifically? The circadian disruption in ME/CFS may alter the optimal dose compared to the general population.\n\n3. Is there a biomarker (genetic, metabolomic, or clinical) that predicts individual position on the dose-response curve for common ME/CFS medications?\n\n4. Do ME/CFS patients as a population have a left-shifted dose-response curve (same shape, lower optimal dose), or do they have a differently shaped curve entirely?\n\n---\n\n### Type 6: Withdrawal Effects\n\n#### Sub-Patterns\n\n1. **Discontinuation syndrome (SSRI/SNRI)** -- Flu-like symptoms, \"brain zaps\" (paresthesias), emotional lability, insomnia, dizziness. Onset 1-3 days after stopping; can last weeks. In ME/CFS patients, these symptoms overlap heavily with baseline disease symptoms, making it difficult to distinguish withdrawal from disease flare. This overlap is clinically dangerous because it can lead to both missed withdrawal (attributed to ME/CFS worsening) and unnecessary drug reinstatement (ME/CFS flare attributed to withdrawal).\n\n2. **Corticosteroid withdrawal and adrenal suppression** -- Abrupt discontinuation of corticosteroids after prolonged use can cause adrenal crisis (hypotension, fatigue, nausea -- all of which overlap with ME/CFS symptoms). The project already mentions fludrocortisone tapering. Even short courses (2 weeks) of oral corticosteroids can suppress the HPA axis enough to require gradual tapering.\n\n3. **Antihistamine rebound** -- Discontinuation of regular antihistamine use can cause rebound histamine release and worsening of symptoms beyond baseline. In MCAS patients, this can be severe: stopping cetirizine abruptly may trigger a mast cell activation flare. The recommendation is gradual dose reduction over 1-2 weeks.\n\n4. **Sleep medication withdrawal insomnia** -- Abrupt discontinuation of benzodiazepines, Z-drugs, or even melatonin can cause rebound insomnia lasting days to weeks. In ME/CFS patients, where sleep quality is already fragile and poor sleep directly triggers PEM, withdrawal insomnia can cascade into a disease flare.\n\n5. **Stimulant discontinuation** -- The patient's case documents this well (lines 67-74 of `06-gestion-medicale.tex`): Ritalin day followed by non-Ritalin day produces autonomic events, trembling, excessive sleep. This is better characterized as rebound than withdrawal (symptoms are exaggerated pre-existing symptoms, not new symptoms), but the clinical management considerations are similar: either consistent daily use or complete abstinence may be preferable to intermittent use.\n\n6. **Supplement discontinuation effects** -- Often overlooked: abrupt stopping of high-dose magnesium can cause muscle cramping and arrhythmia risk; stopping CoQ10 after long-term use may cause temporary energy decline; stopping high-dose B vitamins can unmask functional deficiencies as metabolic pathways adjusted to the supplement reduce. These are rarely discussed as \"withdrawal\" but are clinically relevant.\n\n#### Treatment Implications\n\n1. **Universal tapering guidelines**: Develop a reference table of tapering schedules for every drug class used in ME/CFS. Include specific schedules with percentage reductions and timeframes rather than vague \"taper slowly\" advice.\n\n2. **Withdrawal vs. relapse distinction protocol**: When symptoms appear after discontinuation, implement a structured waiting period (typically 2-4 weeks for most withdrawal syndromes) before concluding that the drug was needed. Premature reinstatement locks patients into unnecessary long-term medication use.\n\n3. **Cross-taper protocols**: When switching between medications in the same class (e.g., one antihistamine to another), overlap the taper-down and taper-up to avoid a withdrawal gap.\n\n4. **ME/CFS-specific withdrawal risk awareness**: Educate patients that their baseline symptoms will make withdrawal harder to recognize, and that any unexplained symptom worsening within 1-4 weeks of stopping a medication should be evaluated as possible withdrawal.\n\n5. **Supplement discontinuation planning**: When patients need to stop supplements (cost, availability, travel), provide tapering guidance rather than abrupt discontinuation, especially for magnesium, B vitamins, and CoQ10.\n\n#### Research Questions\n\n1. Is the duration of SSRI discontinuation syndrome longer in ME/CFS patients than in the general population, given the overlap with baseline neurological symptoms?\n\n2. Does MCAS status predict antihistamine withdrawal severity? If so, MCAS patients may require slower tapers.\n\n3. What is the optimal pattern for stimulant use in ME/CFS: daily consistent use, scheduled intermittent use (e.g., weekdays only), or as-needed use? The patient case suggests intermittent use causes rebound, but which of the alternatives is safer?\n\n4. Can gradual supplement discontinuation protocols prevent the \"supplement withdrawal\" phenomenon, and how long should the taper be for magnesium, CoQ10, and B12?\n\n---\n\n## C. Patient Case Application\n\nFor the patient profile described (moderate-severe ME/CFS, dysautonomia, MCAS, tinnitus, cognitive impairment; taking LDN, antihistamines, beta-blockers, melatonin, supplements):\n\n### Most Critical Patterns to Document\n\n1. **Ritalin rebound pattern** (already documented, lines 67-74): This is a textbook example of Type 7 (rebound effects). The day-on/day-off pattern with autonomic crisis the next day demands urgent clinical attention. Treatment implication: discuss with physician whether to switch to consistent daily dosing or discontinue.\n\n2. **LDN dose optimization** (LDN alternating 3mg/4mg, line 6): Inconsistent dosing prevents steady-state pharmacokinetics and makes dose-response evaluation impossible. This maps to Type 5 (dose-dependent curves). Treatment implication: standardize to one dose and evaluate for minimum 6-8 weeks before adjusting.\n\n3. **Cetirizine as sole MCAS treatment**: If cetirizine is abruptly discontinued (travel, forgot), the patient is at risk for antihistamine rebound (Type 6/7) combined with MCAS flare. The recommendation for a full MCAS protocol (adding famotidine, quercetin) is already in the report.\n\n4. **Stimulant-enabled overactivity**: The Ritalin/modafinil pattern enables cognitive function without changing metabolic capacity (Type 4 variant). The documented heart rate limit (97 bpm) provides an objective safeguard, but the patient needs explicit education about the energy-borrowing concept.\n\n5. **Melatonin dose optimization**: If the patient is on a standard 3-5mg dose, this may actually be suboptimal. Chronopharmacology literature suggests physiological doses (0.3-0.5mg) may be more effective for circadian resetting (Type 5). Worth discussing with physician.\n\n6. **Supplement-drug interactions**: CoQ10 is a mild CYP inhibitor. Magnesium affects absorption of many drugs. Alpha-lipoic acid can affect blood glucose levels and potentially interact with autonomic medications. B12 (methylcobalamin vs. cyanocobalamin) affects methylation pathways relevant to drug metabolism. None of these are dangerous individually, but the combination deserves a pharmacist review (Additional Pattern 6: polypharmacy).\n\n7. **Tinnitus as drug-response biomarker**: The monitoring protocol already documents tinnitus tracking (line 13 of `10-surveillance-interactions.tex`). Tinnitus often worsens with specific drugs (aspirin, some antibiotics) and can be an early warning signal of drug toxicity or dosing issues.\n\n### Recommended Actions for This Patient\n\n- Stabilize LDN at single dose (3mg or 4mg, not alternating)\n- Address Ritalin intermittent use pattern (discuss with physician: daily vs. stop)\n- Consider melatonin dose reduction trial (current dose to 0.5mg)\n- Pharmacist review of full medication + supplement regimen for interactions\n- Pre-plan cetirizine taper protocol in case discontinuation is ever needed\n\n---\n\n## D. Pediatric Adaptations\n\n### Effect Types Ranked by Pediatric Importance\n\n1. **Energy-Before-Mood Paradox (Type 4) -- HIGHEST PRIORITY**: Adolescents are already at elevated suicide risk. The energy-before-mood paradox is the most dangerous of all 6 types in this population. The FDA black box warning on SSRIs for under-25 reflects this. In pediatric ME/CFS, the combination of chronic illness burden, social isolation (school absence), identity disruption, and activating medication creates a uniquely dangerous risk profile. Every pediatric medication section must address this.\n\n2. **Dose-Dependent Benefit Curves (Type 5) -- HIGH PRIORITY**: Pediatric pharmacokinetics differ substantially from adult. CYP3A4 activity is higher in children than adults, paradoxically meaning some drugs are metabolized FASTER (requiring higher per-kg doses). But CYP2D6 maturation varies -- poor metabolizer phenotype may be more impactful. Weight-based dosing is necessary but insufficient; developmental pharmacokinetics must be considered.\n\n3. **Withdrawal Effects (Type 6) -- HIGH PRIORITY**: Adolescents may have less insight into withdrawal symptoms and may not report them. Additionally, school attendance pressures may lead to abrupt medication changes (stopping because of side effects interfering with school) without proper tapering.\n\n4. **Transient Adverse Effects (Type 1) -- MODERATE PRIORITY**: Children may lack the vocabulary to describe transient effects and may express them behaviorally (irritability, school refusal, crying) rather than verbally. Caregivers need specific behavioral markers to monitor.\n\n5. **Therapeutic Lag (Type 2) -- MODERATE PRIORITY**: Children and adolescents (and their parents) may have less patience for therapeutic lag, especially when school is at stake. Explicit timeline contracts with both the patient AND the parents/school are essential.\n\n6. **Herxheimer Reactions (Type 3) -- LOWER PRIORITY in pediatric but still important**: Less relevant because antimicrobial treatment is less common in pediatric ME/CFS, but needs to be addressed if antimicrobials are used.\n\n### Pediatric-Specific Variations\n\n- **Developmental CYP450 variation**: Drug metabolism capacity changes throughout childhood and adolescence. Doses that are appropriate for a 12-year-old may be too high or too low for a 16-year-old.\n- **Puberty-related pharmacokinetic shifts**: Hormonal changes during puberty alter drug distribution (body fat percentage changes), metabolism (sex hormone effects on CYP enzymes), and receptor sensitivity.\n- **School-medication interaction**: Timing of medications must account for school schedule. Sedating medications cannot be taken before school. Stimulants must wear off by bedtime. This constrains chronopharmacological optimization.\n- **Compliance challenges**: Adolescents may skip doses, double doses, or share medications. Medication education must be delivered directly to the patient (age-appropriate), not only to parents.\n- **Growth monitoring**: Long-term medications (stimulants, corticosteroids) can affect growth velocity. Regular monitoring of height and weight percentiles is essential.\n- **Long-term developmental effects**: The developing brain is more sensitive to psychoactive medications. Effects on neurodevelopment from chronic medication use in ME/CFS adolescents are essentially unstudied.\n\n---\n\n## E. Safety Priority Ranking\n\n### Tier 1: Life-Threatening if Unrecognized\n\n1. **Energy-Before-Mood Paradox (Type 4)**: Suicide risk during activation phase. Monitoring required at days 3, 7, 14, 21 after starting any activating medication. Crisis resources must be proactively provided. Especially critical in adolescents.\n\n2. **Corticosteroid withdrawal / adrenal crisis (Type 6 sub-pattern)**: Can cause hemodynamic collapse. Mandatory tapering schedule. Never discontinue abruptly after more than 1 week of use.\n\n3. **Stimulant-enabled overactivity leading to severe PEM crash (Type 4 variant / Additional Pattern 2)**: While not immediately life-threatening, severe PEM can cause functional decline that does not fully recover. The patient's Ritalin rebound with autonomic crisis demonstrates this risk.\n\n### Tier 2: Clinically Dangerous if Unrecognized\n\n4. **Herxheimer vs. adverse reaction confusion (Type 3)**: If a true adverse reaction is mistakenly identified as Herxheimer and treatment is continued, the patient may sustain organ damage. Conversely, if a Herxheimer is mistaken for adverse reaction and treatment is stopped, a potentially effective treatment is abandoned.\n\n5. **Serotonin syndrome risk from cumulative polypharmacy (Additional Pattern 6)**: Multiple mild serotonergic agents (SSRIs + tramadol + supplements like St. John's Wort + LDN) can sum to dangerous serotonin levels. Requires pharmacist review of complete medication list.\n\n6. **Antihistamine rebound in MCAS patients (Type 6/7 sub-pattern)**: Abrupt discontinuation can trigger severe mast cell activation flare requiring emergency treatment.\n\n### Tier 3: Clinically Important, Non-Emergency\n\n7. **Premature drug discontinuation from transient effects (Type 1)**: Patient loses access to potentially beneficial treatment. Requires pre-treatment counseling.\n\n8. **Therapeutic lag leading to treatment abandonment (Type 2)**: Patient discontinues effective treatment before it has had time to work. Requires timeline contracts.\n\n9. **Suboptimal dosing on wrong part of dose-response curve (Type 5)**: Patient suffers side effects from excessive dose or gets no benefit from inadequate dose. Requires systematic dose-finding.\n\n10. **Chronopharmacological mismatch (Additional Pattern 5)**: Drug taken at wrong time of day produces suboptimal effect or unnecessary side effects. Requires timing review.\n\n### Monitoring Requirements by Priority\n\n| Priority | Pattern | Monitoring | Frequency | By Whom |\n|----------|---------|-----------|-----------|---------|\n| 1 | Energy-before-mood | Suicide screening (PHQ-9, C-SSRS) | Days 3,7,14,21 | Clinician + caregiver |\n| 1 | Corticosteroid withdrawal | Blood pressure, cortisol, symptoms | Daily during taper | Clinician |\n| 1 | Stimulant overactivity | Heart rate monitoring, activity log | Continuous | Patient + caregiver |\n| 2 | Herxheimer vs. ADR | CRP, tryptase, symptom profile | During suspected reaction | Clinician |\n| 2 | Serotonin risk | Complete medication review | At every new drug addition | Pharmacist |\n| 2 | Antihistamine rebound | Symptom diary | Daily during any taper | Patient |\n| 3 | Transient effects | Symptom diary | Daily first 2-4 weeks | Patient |\n| 3 | Therapeutic lag | Domain-specific symptom tracking | Weekly | Patient + clinician |\n| 3 | Dose optimization | Multi-domain symptom tracking | At each dose change | Patient + clinician |\n\n### Patient Education Priorities (Ordered)\n\n1. \"New medications may make you feel worse before they make you feel better. Here is what to expect and when to call us.\"\n2. \"Feeling more energetic does NOT mean you can do more. Your actual capacity has not changed. Use your heart rate monitor.\"\n3. \"Never stop a medication suddenly without consulting us, especially corticosteroids, antidepressants, or antihistamines.\"\n4. \"Higher doses are not always better. Tell us if increasing the dose makes things worse, not just if it does not help.\"\n5. \"Keep a simple daily symptom diary. This is the most important tool for figuring out what is working.\"\n\n---\n\n## Deliverables Verification\n\n- **Additional effect patterns**: 7 identified (target was >=3)\n- **Sub-patterns total**: 30 sub-patterns across the 6 planned types (target was >=18)\n- **Treatment implications total**: 24 treatment implications (target was >=18)\n- **Research questions total**: 22 research questions (target was >=18)\n\n---\n\n## Key Source Files Referenced\n\n- `/home/nicky/code/health-me-cfs/.claude/plans/medication-effect-patterns.md` -- Full Phase 6 implementation plan\n- `/home/nicky/code/health-me-cfs/.claude/plans/06-phase-medication-effects.md` -- Phase 6 summary\n- `/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/06-gestion-medicale.tex` -- Patient medication management (LDN, cetirizine, Ritalin, modafinil)\n- `/home/nicky/code/health-me-cfs/patients/yannick/medical report/contents/10-surveillance-interactions.tex` -- Monitoring protocols and drug trial criteria\n- `/home/nicky/code/health-me-cfs/contents/part3-treatment/ch15-medications-systems.tex` -- CYP450 interactions (cimetidine)\n\nSources:\n- [Medication use and symptomology in North American women with ME/CFS (Frontiers, 2025)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1543158/full)\n- [Patient-reported treatment outcomes in ME/CFS and long COVID (PNAS)](https://www.pnas.org/doi/10.1073/pnas.2426874122)\n- [Medication Responses in Chronic Fatigue Syndrome (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3512701/)\n- [Low-Dose Naltrexone for ME/CFS: Dose-Finding Trial (ClinicalTrials.gov)](https://clinicaltrials.gov/study/NCT07285473)\n- [LDN Dosing Guide 2024 (LDN Research Trust)](https://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf)\n- [Bateman Horne Center LDN Guide](https://batemanhornecenter.org/wp-content/uploads/2024/09/Low-Dose-Naltrexone-LDN-20240911.pdf)\n- [Antidepressant-Induced Suicidality: An Update (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6493906/)\n- [SSRIs and suicidal behaviour: population-based cohort study (Nature)](https://www.nature.com/articles/s41386-021-01179-z)\n- [Rebound effect, discontinuation, and withdrawal syndromes (Pharmacological Reports, 2024)](https://link.springer.com/article/10.1007/s43440-024-00689-z)\n- [Dependence, withdrawal and rebound of CNS drugs (Brain Communications)](https://academic.oup.com/braincomms/article/1/1/fcz025/5588408)\n- [Circadian Variation in Efficacy of Medications (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8268638/)\n- [Optimizing Chronotherapy in Psychiatric Care (PMC, 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11586979/)\n- [Oral medications for POTS: systematic review (Frontiers Neurology, 2024)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1515486/full)\n- [MCAS: up-to-date review (PMC, 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11212760/)\n- [Pharmacological treatment options for MCAS (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4903110/)\n- [Developmental Pharmacokinetics in Pediatric Populations (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4341411/)\n- [Pediatric pharmacokinetics: key considerations (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4345950/)\n- [Considerations for Pediatric ME/CFS (CDC)](https://www.cdc.gov/me-cfs/hcp/clinical-care/pediatric-me-cfs.html)"}],"stop_reason":null,"stop_sequence":null,"usage":{"input_tokens":1001,"cache_creation_input_tokens":3112,"cache_read_input_tokens":36510,"cache_creation":{"ephemeral_5m_input_tokens":0,"ephemeral_1h_input_tokens":3112},"output_tokens":1,"service_tier":"standard","inference_geo":"not_available"}},"requestId":"req_011CYEBy3tV9aXzmsE4eREcg","type":"assistant","uuid":"cb7c21af-e956-4ba8-8788-4fbef07cfd7d","timestamp":"2026-02-17T19:29:50.393Z"}
